

1 **TILTomorrow today: dynamic factors predicting changes**  
2 **in intracranial pressure treatment intensity after traumatic**  
3 **brain injury**

4  
5 **Shubhayu Bhattacharyay<sup>1,2,3,\*</sup>, Florian D van Leeuwen<sup>4</sup>, Erta Beqiri<sup>5</sup>, Cecilia**  
6 **Åkerlund<sup>6</sup>, Lindsay Wilson<sup>7</sup>, Ewout W Steyerberg<sup>4</sup>, David W Nelson<sup>6</sup>, Andrew I R**  
7 **Maas<sup>8,9</sup>, David K Menon<sup>1</sup>, Ari Ercole<sup>1,10</sup>, and the CENTER-TBI investigators and**  
8 **participants<sup>†</sup>**

9  
10 <sup>1</sup>Division of Anaesthesia, University of Cambridge, Cambridge, United Kingdom.

11 <sup>2</sup>Department of Clinical Neurosciences, University of Cambridge, Cambridge, United  
12 Kingdom.

13 <sup>3</sup>Harvard Medical School, Boston, MA, USA.

14 <sup>4</sup>Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden,  
15 The Netherlands.

16 <sup>5</sup>Brain Physics Laboratory, Division of Neurosurgery, University of Cambridge,  
17 Cambridge, United Kingdom.

18 <sup>6</sup>Department of Physiology and Pharmacology, Section for Perioperative Medicine and  
19 Intensive Care, Karolinska Institutet, Stockholm, Sweden.

20 <sup>7</sup>Division of Psychology, University of Stirling, Stirling, United Kingdom.

21 <sup>8</sup>Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium.

22 <sup>9</sup>Department of Translational Neuroscience, Faculty of Medicine and Health Science,  
23 University of Antwerp, Antwerp, Belgium.

24 <sup>10</sup>Cambridge Centre for Artificial Intelligence in Medicine, Cambridge, United Kingdom.

25  
26 \*Corresponding author: [sb2406@cam.ac.uk](mailto:sb2406@cam.ac.uk) (SB)

27 †A full list of the CENTER-TBI investigators and participants are listed after the  
28 acknowledgements.

## 29 ABSTRACT

30  
31 Practices for controlling intracranial pressure (ICP) in traumatic brain injury (TBI) patients  
32 admitted to the intensive care unit (ICU) vary considerably between centres. To help  
33 understand the rational basis for such variance in care, this study aims to identify the  
34 patient-level predictors of changes in ICP management. We extracted all heterogeneous  
35 data (2,008 pre-ICU and ICU variables) collected from a prospective cohort ( $n=844$ , 51  
36 ICUs) of ICP-monitored TBI patients in the Collaborative European NeuroTrauma  
37 Effectiveness Research in TBI (CENTER-TBI) study. We developed the TILTomorrow  
38 modelling strategy, which leverages recurrent neural networks to map a token-embedded  
39 time series representation of all variables (including missing values) to an ordinal,  
40 dynamic prediction of the following day's five-category therapy intensity level ( $TIL^{(Basic)}$ )  
41 score. With 20 repeats of 5-fold cross-validation, we trained TILTomorrow on different  
42 variable sets and applied the TimeSHAP (temporal extension of SHapley Additive  
43 exPlanations) algorithm to estimate variable contributions towards predictions of next-day  
44 changes in  $TIL^{(Basic)}$ . Based on Somers'  $D_{xy}$ , the full range of variables explained 68%  
45 (95% CI: 65–72%) of the ordinal variation in next-day changes in  $TIL^{(Basic)}$  on day one and  
46 up to 51% (95% CI: 45–56%) thereafter, when changes in  $TIL^{(Basic)}$  became less frequent.  
47 Up to 81% (95% CI: 78–85%) of this explanation could be derived from non-treatment  
48 variables (i.e., markers of pathophysiology and injury severity), but the prior trajectory of  
49 ICU management significantly improved prediction of future de-escalations in ICP-  
50 targeted treatment. Whilst there was no significant difference in the predictive  
51 discriminability (i.e., area under receiver operating characteristic curve [AUC]) between  
52 next-day escalations (0.80 [95% CI: 0.77–0.84]) and de-escalations (0.79 [95% CI: 0.76–  
53 0.82]) in  $TIL^{(Basic)}$  after day two, we found specific predictor effects to be more robust with  
54 de-escalations. The most important predictors of day-to-day changes in ICP management  
55 included preceding treatments, age, space-occupying lesions, ICP, metabolic  
56 derangements, and neurological function. Serial protein biomarkers were also important  
57 and may serve a useful role in the clinical armamentarium for assessing therapeutic  
58 needs. Approximately half of the ordinal variation in day-to-day changes in  $TIL^{(Basic)}$  after  
59 day two remained unexplained, underscoring the significant contribution of unmeasured  
60 factors or clinicians' personal preferences in ICP treatment. At the same time, specific  
61 dynamic markers of pathophysiology associated strongly with changes in treatment  
62 intensity and, upon mechanistic investigation, may improve the timing and personalised  
63 targeting of future care.

## 64 MAIN TEXT

65

## 66 Introduction

67

68 When traumatic brain injury (TBI) patients are admitted to the intensive care unit (ICU), a  
69 core focus of their care is to protect and promote potential recovery in brain tissue by  
70 either preventing or mitigating raised intracranial pressure (ICP).<sup>1</sup> To date, the  
71 heterogeneous pathophysiological mechanisms that elevate ICP after TBI are not  
72 sufficiently characterised for patient-tailored treatment (i.e., precision medicine).<sup>2,3</sup>  
73 Therefore, consensus-based guidelines<sup>4,5</sup> encourage a precautionary, stepwise  
74 approach<sup>6</sup> to ICP management, in which therapeutic intensity – defined by the perceived  
75 risk and complexity of each treatment plan – is incrementally escalated until adequate  
76 ICP control is achieved. The overall intensity of a patient’s ICP management can be  
77 measured on the latest Therapy Intensity Level (TIL) scale,<sup>7</sup> which was developed by the  
78 interagency TBI Common Data Elements (CDE) scheme<sup>8</sup> and prospectively validated  
79 thereafter.<sup>7,9</sup>


80

81 An analysis of high-TIL treatment administration across 52 ICUs participating in the  
82 Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)  
83 study<sup>10,11</sup> revealed frequent deviation from the recommended stepwise approach, even  
84 with ICP monitoring.<sup>12</sup> In fact, there was substantial between-centre variation in ICP  
85 management (according to TIL) without commensurate variation in six-month functional  
86 outcome on the Glasgow Outcome Scale – Extended (GOSE).<sup>13,14</sup> Baseline injury  
87 severity factors, imaging results, and ICP explained only 8.9% of the pseudo-variance in  
88 dichotomised high-TIL treatment use.<sup>12</sup> These results raised the questions about whether  
89 contemporary ICP management is performed in a systematic, rational manner in practice  
90 and whether some patients are being exposed to unnecessary risks with high-TIL  
91 therapies. Answering these questions requires consideration of a patient’s full, time-  
92 varying clinical course as well as a more detailed representation of different levels of the  
93 TIL scale.

94

95 As a first step towards answering the questions above, we aim to identify factors  
96 associated with ICP-targeted treatment decisions on an individual patient level.  
97 Expanding upon our previous work,<sup>13,15</sup> we propose a modelling strategy (TILTomorrow)  
98 which dynamically predicts next-day TIL<sup>(Basic)</sup> – the five-category version of TIL – from all  
99 pre-ICU and ICU data prospectively recorded for the CENTER-TBI study (Fig. 1). Our  
100 primary objective in developing TILTomorrow was to determine how well a patient’s full  
101 clinical course can predict upcoming changes in ICP treatment intensity. Our second  
102 objective was to estimate the differential contribution of pathophysiological severity, the  
103 preceding trajectory of treatment, and unmeasured factors (e.g., personal treatment  
104 preferences) towards explanation of next-day changes made to TIL<sup>(Basic)</sup>. Our third  
105 objective was to mine the full dataset for dynamic predictors of day-to-day changes in  
106 TIL<sup>(Basic)</sup>.

107



109 **Fig. 1. TILTomorrow prediction task and modelling strategy.** All shaded regions surrounding curves  
 110 are 95% confidence intervals derived using bias-corrected bootstrapping (1,000 resamples) to represent  
 111 the variation across the patient population and across the 20 repeated five-fold cross-validation partitions.  
 112 (a) Illustration of the TILTomorrow dynamic prediction task on a sample patient's timeline of ICU stay. The  
 113 objective of the task is to predict the next-day  $TIL^{(Basic)}$  score at each calendar day of a patient's ICU stay.  
 114 The prediction is dynamic, updated for each calendar day, and must account for temporal variation of  
 115 variables across all preceding days using a time-series model ( $f_t$ ). (b) Illustration of the TILTomorrow  
 116 modelling strategy on a sample patient's timeline of ICU stay. Each patient's ICU stay is first discretised

117 into non-overlapping time windows, one for each calendar day. From each time window, values for up to  
118 979 dynamic variables were combined with values for up to 1,029 static variables to form the variable set.  
119 The variable values were converted to tokens by discretising numerical values into 20-quantile bins from  
120 the training set and removing special formatting from text-based entries. Through an embedding layer, a  
121 vector was learned for each token encountered in the training set, and tokens were replaced with these  
122 vectors. A positive relevance weight, also learned for each token, was used to weight-average the vectors  
123 of each calendar day into a single, low-dimensional vector. The sequence of low-dimensional vectors  
124 representing a patient's ICU stay were fed into a gated recurrent neural network (RNN). The RNN outputs  
125 were then decoded at each time window into an ordinal prognosis of next-day TIL<sup>(Basic)</sup> score. The highest-  
126 intensity treatments associated with each threshold of TIL<sup>(Basic)</sup> are decoded in Table 1. (c) Probability  
127 calibration slope, at each threshold of next-day TIL<sup>(Basic)</sup>, for models trained on the full variable set. The  
128 ideal calibration slope of one is marked with a horizontal orange line. (d) Ordinal probability calibration  
129 curves at four different days after ICU admission. The diagonal dashed line represents the line of perfect  
130 calibration. The values in each panel correspond to the maximum absolute error (95% confidence interval)  
131 between the curve and the perfect calibration line. Abbreviations: CT=computerised tomography,  
132 ER=emergency room,  $f_t$ =time-series model, GRU=gated recurrent unit, Hx=history, ICP=intracranial  
133 pressure, ICU=intensive care unit, LSTM=long short-term memory, N/A=not available, NF-L=neurofilament  
134 light chain, SES=socioeconomic status, TIL=Therapy Intensity Level, TIL<sup>(Basic)</sup>=condensed, five-category  
135 TIL scale as defined in Table 1, VE=vascular endothelial.

136

## 137 **Methods**

138

### 139 ***Study design and participants***

140

141 CENTER-TBI is a longitudinal, observational cohort study (NCT02210221) involving 65  
142 medical centres across 18 European countries and Israel.<sup>10,11</sup> Patients were recruited  
143 between 19 December 2014 and 17 December 2017 if they met the following criteria: (1)  
144 presentation within 24 hours of a TBI, (2) clinical indication for a computerised  
145 tomography (CT) scan, and (3) no severe pre-existing neurological disorder. In  
146 accordance with relevant laws of the European Union and the local country, ethical  
147 approval was obtained for each site, and written informed consent by the patient or legal  
148 representative was documented electronically. The list of sites, ethical committees,  
149 approval numbers, and approval dates can be found online: [https://www.center-](https://www.center-tbi.eu/project/ethical-approval)  
150 [tbi.eu/project/ethical-approval](https://www.center-tbi.eu/project/ethical-approval). The project objectives and design of CENTER-TBI have  
151 been described in detail previously.<sup>10,11</sup>

152

153 In this work, we apply the following additional inclusion criteria: (1) primary admission to  
154 the ICU, (2) at least 16 years old at ICU admission, (3) at least 24 hours of ICU stay, (4)  
155 invasive ICP monitoring, (5) no decision to withdraw life-sustaining therapies (WLST) on  
156 the first day of ICU stay, and (6) availability of daily TIL assessments from at least two  
157 consecutive days.

158

### 159 ***Therapy intensity level (TIL)***

160

161 The endpoint for the TILTomorrow dynamic prediction task (Fig. 1a) is the next-day  
162 TIL<sup>(Basic)</sup> score. The TIL<sup>(Basic)</sup> scale was developed through an international expert panel  
163 to serve as a five-category summary of the full, 38-point TIL score.<sup>8</sup> TIL<sup>(Basic)</sup> categorises  
164 overall ICP treatment intensity over a given period of time by selecting the highest

165 classification of ICP control amongst all treatments administered in that period of time, as  
166 defined in Table 1. By convention, a decompressive craniectomy for refractory intracranial  
167 hypertension is scored with  $TIL^{(Basic)}=4$  (i.e., extreme ICP control) for every subsequent  
168 timepoint. As described later, we account for this effect in our analysis by: (1) referencing  
169 TILTomorrow performance against simply carrying forward the last-available  $TIL^{(Basic)}$   
170 score and against models trained without treatment (e.g. incidence of decompressive  
171 craniectomy) or clinician-impression (e.g., reason for decompressive craniectomy)  
172 variables, and (2) focusing only on variables that occur at least a day before a change in  
173  $TIL^{(Basic)}$ . Since daily use of  $TIL^{(Basic)}$  was prospectively validated,<sup>7</sup> we calculate the  
174  $TIL^{(Basic)}$  score over each available calendar day of a patient's ICU stay. For the CENTER-  
175 TBI study, information pertaining to the  $TIL^{(Basic)}$  treatments (Table 1) was recorded on  
176 days 1–7, 10, 14, 21, and 28 of ICU stay.  $TIL^{(Basic)}$  score calculations were excluded on  
177 or after the day of any WLST decision. As an overall summary metric, we also calculated  
178  $TIL^{(Basic)}_{median}$  – the median of the daily  $TIL^{(Basic)}$  scores over days 1–7 of ICU stay.

179  
180 We elected not to use the full TIL score as the model endpoint since it is a point-sum  
181 (rather than a truly categorical) score, and the same value changes in TIL can be the  
182 result of changing treatments across different intensities. For instance, administering  
183 head elevation, low-volume cerebrospinal fluid drainage, and low-dose mannitol is  
184 numerically 'equivalent' to performing a last-resort decompressive craniectomy.<sup>7</sup> On the  
185 contrary, changes in  $TIL^{(Basic)}$  correspond to transitions across specific, interpretable  
186 bands of treatment intensity (Table 1).

187

**Table 1. TIL<sup>(Basic)</sup> scale treatments and representation in study population**

Classification of ICP control	ICP-targeting treatment	Study representation (count)	
		Patients (844 total)	Centres (51 total)
<b>(4) Extreme</b>	High-dose propofol or barbiturates (metabolic suppression)	490 (58%)	50 (98%)
	Intensive hyperventilation ( $P_aCO_2 < 30$ mmHg)	315 (37%)	46 (90%)
	Therapeutic hypothermia ( $< 35^\circ C$ )	61 (7.2%)	24 (47%)
	Intracranial operation for progressive mass lesion (not scheduled at admission)	93 (11%)	31 (61%)
	Intracranial operation for progressive mass lesion (not scheduled at admission)	149 (18%)	40 (78%)
	Decompressive craniectomy for refractory intracranial hypertension*	76 (9.0%)	29 (57%)
<b>(3) Moderate</b>	High-volume CSF drainage ( $\geq 120$ mL/24h)	344 (41%)	47 (92%)
	Moderate hyperventilation ( $30 \leq P_aCO_2 < 35$ mmHg)	212 (25%)	41 (80%)
	Higher-dose mannitol ( $> 2$ g/kg/24h)	235 (28%)	41 (80%)
	Higher-dose hypertonic saline ( $> 0.3$ g/kg/24h)	45 (5.3%)	22 (43%)
	Higher-dose hypertonic saline ( $> 0.3$ g/kg/24h)	128 (15%)	33 (65%)
	Cooling for ICP control ( $\geq 35^\circ C$ )	146 (17%)	32 (63%)
<b>(2) Mild</b>	Higher-dose sedation for ICP control (not aiming for burst suppression)	645 (76%)	50 (98%)
	Low-volume CSF drainage ( $< 120$ mL/24h)	561 (66%)	48 (94%)
	Fluid loading for CPP management	221 (26%)	41 (80%)
	Vasopressor therapy for CPP management	511 (61%)	48 (94%)
	Mild hyperventilation ( $35 \leq P_aCO_2 < 40$ mmHg)	720 (85%)	50 (98%)
	Lower-dose mannitol ( $\leq 2$ g/kg/24h)	509 (60%)	48 (94%)
	Lower-dose hypertonic saline ( $\leq 0.3$ g/kg/24h)	197 (23%)	41 (80%)
	Lower-dose hypertonic saline ( $\leq 0.3$ g/kg/24h)	303 (36%)	41 (80%)
<b>(1) Basic</b>	Head elevation for ICP control	406 (48%)	45 (88%)
	Nursed flat ( $180^\circ$ ) for CPP management	765 (91%)	50 (98%)
	Lower-dose sedation for mechanical ventilation	123 (15%)	31 (61%)
	Lower-dose sedation for mechanical ventilation	753 (89%)	50 (98%)
<b>(0) None</b>		338 (40%)	48 (94%)

189 The TIL<sup>(Basic)</sup> scale was developed by Maas *et al.*<sup>8</sup> and prospectively validated by Bhattacharyay *et al.*<sup>7</sup> The TIL<sup>(Basic)</sup> score is determined by selecting  
190 the highest classification of ICP control (first column) among all the ICP-targeting treatments (second column) administered to a patient over a  
191 calendar day. The study representation of each TIL<sup>(Basic)</sup> category and each ICP-targeting treatment is the count (and percentage) of patients who  
192 received the corresponding (category of) treatment in the study population as well as the count (and percentage) of centres who administered the  
193 corresponding (category of) treatment in the study population.

194 \*If a decompressive craniectomy is performed as a last resort for refractory intracranial hypertension, its score is included in the day of the operation  
195 and in every subsequent day of ICU stay.

196 Abbreviations: CPP=cerebral perfusion pressure, CSF=cerebrospinal fluid, ICP=intracranial pressure, ICU=intensive care unit,  $P_aCO_2$ =partial  
197 pressure of carbon dioxide in arterial blood, TIL=Therapy Intensity Level scale, TIL<sup>(Basic)</sup>=condensed TIL scale.

## 198 **Model variables**

199  
 200 We extracted all variables collected before and during ICU stays for the CENTER-TBI  
 201 core study<sup>11</sup> (v3.0, ICU stratum) using Opal database software.<sup>16</sup> These variables were  
 202 sourced from medical records and online test results and include structured (i.e.,  
 203 numerical, binary, or categorical), unstructured (i.e., free text), and missing values. We  
 204 manually excluded variables which explicitly indicate death or WLST (Supplementary  
 205 Table S1), and, if a decision to WLST was made during any point of a patient’s ICU stay,  
 206 we only extracted model variables before the timestamp of WLST decision. We also  
 207 added features extracted from automatically segmented and expert-corrected high-  
 208 resolution CT and magnetic resonance (MR) images. These features correspond to the  
 209 type, location, and volume of space-occupying lesions, and the process of their extraction  
 210 has been described in detail previously.<sup>17,18</sup> In total, we included 2,008 variables: 1,029  
 211 static (i.e., fixed at ICU admission) variables and 979 dynamic variables (i.e., collected  
 212 during ICU stay) with varying sampling frequencies. We qualitatively organised the  
 213 variables into the nine categories listed in Table 2 and further indicated whether variables  
 214 represented an intervention during ICU admission (e.g., administration and type of  
 215 glucose management) or a physician-based impression (e.g., reason for not pursuing  
 216 intracranial surgery following CT scan, Supplementary Table S2). Descriptions for each  
 217 of the variables can be viewed online at the CENTER-TBI data dictionary:  
 218 <https://www.center-tbi.eu/data/dictionary>.

219  
 220 **Table 2. Variable count per category and subtype**

Category	Example variable	Count by subtypes			
		All	Static	Dynamic	Interventions and physician impressions
Demographics and socioeconomic status	Years of formal education	22	22	0	0
Medical and behavioural history	Number of prior TBIs or concussions	186	186	0	0
Injury characteristics and severity	Airbag deployed during accident	84	84	0	0
Emergency care and ICU admission	Blood transfusion in ER	234	234	0	14
Brain imaging reports	Cortical sulcal effacement	939	425	514	19
Laboratory measurements	Serum level of UCH-L1	228	75	153	6
ICU medications and management	Vasopressor dose	141	3	138	127
ICU vitals and assessments	Types of seizures in past day	125	0	125	0
Surgery and neuromonitoring	Ventriculostomy for CSF drainage	49	0	49	39
<b>Total</b>		<b>2008</b>	<b>1029</b>	<b>979</b>	<b>205</b>

221 Data represent the number of subtype (*column*) variables per category (*row*).  
 222 Abbreviations: CSF=cerebrospinal fluid, ER=emergency room, ICU=intensive care unit, SBP=systolic blood  
 223 pressure, TBI=traumatic brain injury, UCH-L1=ubiquitin carboxy-terminal hydrolase L1.

## 224 225 **TIL Tomorrow modelling strategy**

226



227 Whilst strong predictors of functional outcome after TBI are known, this is not the case  
228 for TIL. Thus, the TILTomorrow modelling strategy was designed to include *all* static and  
229 dynamic variables from CENTER-TBI to produce an evolving prediction of the next  
230 calendar day's TIL<sup>(Basic)</sup> over each patient's ICU stay. The large number of variables  
231 precludes building such a model by manual feature extraction, motivating our flexible  
232 tokenisation-and-embedding approach with no constraints on the number or type of  
233 variables per patient. We trained models, through supervised machine learning, with three  
234 main components based on our prior studies<sup>13,15,19</sup>: (1) a token-embedding encoder, (2)  
235 a gated recurrent neural network (RNN), and (3) an ordinal endpoint output layer. We  
236 created 100 partitions of our patient population for repeated *k*-fold cross-validation (20  
237 repeats, 5 folds) with 15% of each training set randomly set aside as an internal validation  
238 set.

239  
240 ICU stays were partitioned into non-overlapping time windows, one per calendar day (Fig.  
241 1a). Static variables were carried forward across all windows (Fig. 1b). All variables were  
242 tokenised through one of the following methods: (1) for categorical variables, appending  
243 the value to the variable name, (2) for numerical variables, learning the training set  
244 distribution and discretising into 20 quantile bins, (3) for text-based entries, removing all  
245 special characters, spaces, and capitalisation from the text and appending to the variable  
246 name, and (4) for missing values, creating a separate token to designate missingness  
247 (Fig. 1b). We selected 20 quantile bins for discretisation based on optimal performance  
248 in our previous work.<sup>13,19</sup> By labelling missing values with separate tokens instead of  
249 imputing them, the models could learn potentially significant patterns of missingness and  
250 integrate a diverse range of missing data without needing to validate the assumptions of  
251 imputation methods on each variable.<sup>20</sup> During training, the models learned a low-  
252 dimensional vector (of either 128, 256, 512, or 1,024 units) and a 'relevance' weight for  
253 each token in the training set. Therefore, models would take the unique tokens from each  
254 time window of a patient, replace them with the corresponding vectors, and average the  
255 vectors – each weighted by its corresponding relevance score – into a single vector per  
256 time window (Fig. 1b).

257  
258 Each patient's sequence of low-dimensional vectors then fed into a gated RNN – either a  
259 long short-term memory (LSTM) network or a gated recurrent unit (GRU) – to output  
260 another vector per time window. In this manner, the models learned temporal patterns of  
261 variable interactions from training set ICU records and updated outputs with each new  
262 time window of data. Finally, each RNN output vector was decoded with a multinomial  
263 (i.e., softmax) output layer to return a probability at each threshold of next-day TIL<sup>(Basic)</sup>  
264 over time (Fig. 1b). From these outputs, we also calculated the probabilities of TIL<sup>(Basic)</sup>  
265 decreasing, staying the same, or increasing tomorrow in relation to the last available  
266 TIL<sup>(Basic)</sup> score (Supplementary Methods S1). Please note that both threshold-level  
267 probability estimates and estimated probabilities of next-day changes in TIL<sup>(Basic)</sup> are  
268 derived from the outputs of the same model, as described in Supplementary Methods S1.

269  
270 The combinations of hyperparameters – in addition to those already mentioned  
271 (embedding vector dimension and RNN type) – and the process of their optimisation in  
272 the internal validation sets are reported in Supplementary Methods S2–S3.

273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317

## **Model and information evaluation**

All metrics, curves, and associated confidence intervals (CIs) were calculated on the testing sets using the repeated Bootstrap Bias Corrected Cross-Validation (BBC-CV) method,<sup>21</sup> as described in Supplementary Methods S2. We calculated metrics and CIs at each day directly preceding a day of TIL assessment in our study population (i.e., days 1–6, 9, 13, 20, and 27).

The reliability of model-generated prediction trajectories was assessed through the calibration of output probabilities at each threshold of next-day TIL<sup>(Basic)</sup>. Using the logistic recalibration framework,<sup>22</sup> we first measured calibration slope. Calibration slope less(/greater) than one indicates overfitting(/underfitting).<sup>22</sup> Additionally, we examined smoothed probability calibration curves to detect miscalibrations that might have been overlooked by the logistic recalibration framework.<sup>22</sup>

To evaluate prediction discrimination performance, we calculated the area under the receiver operating characteristic curve (AUC) at each threshold of next-day TIL<sup>(Basic)</sup>. These AUCs are interpreted as the probability of the model correctly discriminating a patient whose next-day TIL<sup>(Basic)</sup> is above a given threshold from one with next-day TIL<sup>(Basic)</sup> below. Moreover, we calculated the AUC for prediction of next-day escalation and de-escalation in TIL<sup>(Basic)</sup>. In this case, the AUC represents the probability of the model correctly discriminating a patient who experienced a day-to-day (de-)escalation in TIL<sup>(Basic)</sup> from one who did not.

We also assessed the information quality achieved by the combination of our modelling strategy and the CENTER-TBI variables in predicting next-day changes in TIL<sup>(Basic)</sup> by calculating Somers'  $D_{xy}$ .<sup>23</sup> In our context, Somers'  $D_{xy}$  is interpreted as the proportion of ordinal variation in day-to-day changes of TIL<sup>(Basic)</sup> that is explained by the variation in model output.<sup>24</sup> The calculation of Somers'  $D_{xy}$  is detailed in Supplementary Methods S4.

We compared the performance of the TILTomorrow modelling strategy trained on the following factors to test their differential contribution to prediction: (1) the full variable set [2,008 variables], (2) all variables excluding physician-based impressions and treatments (e.g., all variables related to TIL) [1,803 variables], and (3) only static variables repeated in each time window [1,029 variables]. Our rationale for these ablated variable sets was to estimate the extent to which: (1) predictable trajectories of care – independent of other measured factors – influence treatment planning and (2) ICP treatments are responding to recorded events that occur over a patient's ICU stay. To serve as our reference for model comparison, we also calculated the performance achieved by simply carrying over the last available TIL<sup>(Basic)</sup> for prediction of next-day TIL<sup>(Basic)</sup>. This reference performance accounts not only for the proportion of the population that did not change in TIL<sup>(Basic)</sup> on a given day but also for the change in the assessment population caused by patient discharge over time.

## 318 **Contributors to transitions in TIL**

319  
320 We applied the TimeSHAP algorithm<sup>25</sup> on testing set predictions to find specific variables  
321 associated with next-day changes in TIL<sup>(Basic)</sup>. TimeSHAP is a temporal extension of the  
322 kernel-weighted SHapley Additive exPlanations (KernelSHAP) algorithm,<sup>26</sup> which  
323 estimates the relative contribution (i.e., Shapley value<sup>27</sup>) of each model input to a specific  
324 patient's model output. In our case, this was done by masking sampled combinations of  
325 tokens (i.e., coalitions) leading up to a patient's next-day change in TIL<sup>(Basic)</sup> and  
326 calculating the difference in trained model output for each combination. A kernel-weighted  
327 linear regression model was then fit between binary coalition masks and resulting model  
328 outputs to estimate the Shapley value for each model input. TimeSHAP extends  
329 KernelSHAP by considering each unique combination of tokens and time windows as its  
330 own feature. Crucially, TimeSHAP made this computationally tractable for our application,  
331 in which models contain many possible tokens, by grouping low-contributing time  
332 windows in the distant past together as a single feature (i.e., temporal coalition pruning).  
333 TimeSHAP, KernelSHAP, and Shapley values are described in greater, mathematical  
334 detail in Supplementary Methods S5.

335  
336 We estimated token-level Shapley values with the TimeSHAP algorithm at both one day  
337 and two days before an upcoming change in TIL<sup>(Basic)</sup>. Our chosen model output for  
338 TimeSHAP was the expected next-day TIL<sup>(Basic)</sup> score, as defined in Supplementary  
339 Methods S5. We then calculated the difference between the estimated Shapley values of  
340 the two consecutive days for each token to derive its  $\Delta$ TimeSHAP value. If a token did  
341 not exist in the window of either of the two days, then its Shapley value for that day was  
342 zero. Therefore,  $\Delta$ TimeSHAP values were interpreted as the contributions of variable  
343 tokens towards the difference in model prediction of next-day TIL<sup>(Basic)</sup> over the two days  
344 directly preceding the change in TIL<sup>(Basic)</sup>, given the patient's full set of tokens. If a variable  
345 had a positive (or negative)  $\Delta$ TimeSHAP value, it was associated with an increased  
346 likelihood of escalation (or de-escalation) in next-day treatment intensity. Moreover, since  
347 the calculation of  $\Delta$ TimeSHAP values required two days of information before the change  
348 in TIL<sup>(Basic)</sup>, we only calculated the variable contributions to day-to-day changes in TIL<sup>(Basic)</sup>  
349 that occurred after day two of ICU stay.

350

## 351 **Results**

352

### 353 **Study population**

354

355 Of the 4,509 patients available for analysis in the CENTER-TBI core study, 844 patients  
356 from 51 ICUs met the inclusion criteria of this work (Supplementary Fig. S1). The median  
357 ICU stay duration of our population was 14 days ( $Q_1$ – $Q_3$ : 8.4–23 days) and 86% ( $n=722$ )  
358 stayed through at least seven calendar days. Since the regularity of TIL<sup>(Basic)</sup> assessments  
359 decreased substantially after 14 days, and since less than half of the population remained  
360 in the ICU for 21 days (Supplementary Fig. S2), we focused our analysis on the first 14  
361 days of ICU stay. Summary characteristics of the overall population as well as those  
362 stratified by whether patients had a day-to-day change in TIL<sup>(Basic)</sup> over their first week in

363 the ICU are detailed in Table 3. On average, patients who did not experience a change  
 364 in TIL<sup>(Basic)</sup> over their first week were significantly younger, had higher baseline ICP  
 365 values, and resulted in poorer functional recovery at six months post-injury (Table 3).  
 366 However, their mean ICU stay duration was not significantly different.

367  
 368 **Table 3. Summary characteristics of the study population stratified by day-to-day changes in**  
 369 **TIL<sup>(Basic)</sup>**

Summary characteristic	Overall ( <i>n</i> =844, 51 centres)	Day-to-day change in TIL <sup>(Basic)</sup> during first week in ICU		<i>p</i> -value <sup>‡</sup>
		Yes ( <i>n</i> =677, 50 centres)	No ( <i>n</i> =167, 40 centres)	
Age [years]	47 (29–61)	48 (30–62)	41 (27–58)	0.047
Sex: Female	212 (25%)	165 (24%)	47 (28%)	0.36
Baseline Glasgow Coma Scale ( <i>n</i> *=795)				0.67
3–8	540 (68%)	426 (67%)	114 (71%)	
9–12	138 (17%)	112 (18%)	26 (16%)	
13–15	117 (15%)	96 (15%)	21 (13%)	
Baseline CT lesions ( <i>n</i> *=730)				
Epidural haematoma	165 (23%)	136 (23%)	29 (19%)	0.36
Intracerebral haemorrhage	594 (81%)	480 (83%)	114 (77%)	0.11
Subdural haematoma	465 (64%)	368 (63%)	97 (65%)	0.76
Traumatic subarachnoid haemorrhage	633 (87%)	502 (86%)	131 (88%)	0.73
First-day mean ICP [mmHg] ( <i>n</i> *=811)	11 (7.0–15)	10. (6.8–14)	12 (8.2–17)	<0.001
TIL <sup>(Basic)</sup> <sub>median</sub>	2 (2–4)	2 (2–3)	4 (2–4)	<0.001
Refractory intracranial hypertension ( <i>n</i> *=836)	143 (17%)	85 (13%)	58 (35%)	<0.001
ICU stay duration [days]	14 (8.4–23)	14 (8.1–23)	14 (8.8–23)	0.90
Six-month GOSE ( <i>n</i> *=738)				0.018
(1) Death	181 (25%)	139 (23%)	42 (29%)	
(2 or 3) Vegetative/lower SD	181 (25%)	154 (26%)	27 (18%)	
(4) Upper SD	70 (9.5%)	48 (8.1%)	22 (15%)	
(5) Lower MD	122 (17%)	96 (16%)	26 (18%)	
(6) Upper MD	73 (10%)	65 (11%)	8 (5.5%)	
(7) Lower GR	55 (7.5%)	42 (7.1%)	13 (8.9%)	
(8) Upper GR	56 (7.6%)	48 (8.1%)	8 (5.5%)	
Baseline prognosis <sup>†</sup> [%] ( <i>n</i> *=749)				
Pr(GOSE>1)	85 (64–94)	85 (66–95)	83 (56–93)	0.010
Pr(GOSE>3)	54 (31–75)	54 (33–76)	52 (24–71)	0.019
Pr(GOSE>4)	40. (22–59)	41 (24–60.)	38 (16–54)	0.010
Pr(GOSE>5)	22 (11–36)	22 (12–38)	19 (8.9–30.)	0.0022
Pr(GOSE>6)	13 (6.7–21)	13 (7.1–22)	11 (5.2–17)	0.0034
Pr(GOSE>7)	5.2 (2.5–9.5)	5.4 (2.7–9.9)	4.2 (2.2–8.6)	0.0071

370 Data are median (Q<sub>1</sub>–Q<sub>3</sub>) for numerical characteristics and *n* (% of column group) for categorical  
 371 characteristics unless otherwise indicated. Units or numerical definitions of characteristics are provided in  
 372 square brackets.

373 \*Limited sample size of non-missing values for characteristic.

374 †Ordinal functional outcome prognostic scores were calculated through tokenised embedding of all clinical  
 375 information in the first 24 hours of ICU stay, as described previously.<sup>15</sup>


376 ‡*p*-values, comparing patients who experienced a day-to-day change in TIL<sup>(Basic)</sup> in the first week of ICU  
 377 stay to those who did not, are derived from Welch's *t*-test for numeric variables and  $\chi^2$  contingency table  
 378 test for categorical variables.

379 Abbreviations: CT=Computerised tomography, GOSE=Glasgow Outcome Scale–Extended, GR=good  
380 recovery, ICP=intracranial pressure, ICU=intensive care unit, MD=moderate disability,  
381  $\text{Pr}(\text{GOSE}>\bullet)$ ="probability of GOSE greater than  $\bullet$  at six months post-injury" as previously calculated from  
382 the first 24 hours of admission,<sup>27</sup> SD=severe disability, TIL=Therapy Intensity Level scale,  
383  $\text{TIL}^{(\text{Basic})}$ =condensed TIL scale as measured in Table 1 for each calendar day,  $\text{TIL}^{(\text{Basic})}_{\text{median}}$ =median  $\text{TIL}^{(\text{Basic})}$   
384 over first week of ICU stay.

385  
386 The representation of each ICP-targeting treatment and  $\text{TIL}^{(\text{Basic})}$  score in our study is  
387 listed in Table 1. The least-represented treatment (higher-dose mannitol) was  
388 administered to 45 patients (5.3%) across 22 ICUs, whereas the least-represented  
389  $\text{TIL}^{(\text{Basic})}$  score ( $\text{TIL}^{(\text{Basic})}=1$ ) applied to 344 patients (41%) across 47 ICUs. A  
390 decompressive craniectomy for refractory intracranial hypertension was performed in 76  
391 patients (9.0%) across 29 ICUs, and the median timepoint for such an operation was day  
392 three ( $Q_1$ – $Q_3$ : two–five) of ICU stay.

393  
394 The distribution of  $\text{TIL}^{(\text{Basic})}$  values at each day of TIL assessment and the transitions of  
395  $\text{TIL}^{(\text{Basic})}$  scores between days of assessment are visualised in Fig. 2a. No more than 2.4%  
396 of the population's  $\text{TIL}^{(\text{Basic})}$  scores were missing at any given assessment day, and the  
397 proportion of patients receiving basic-to-no ICP-targeting treatment (i.e.,  $\text{TIL}^{(\text{Basic})}\leq 1$ )  
398 increased over time (Supplementary Fig. S2). The distribution of day-to-day changes in  
399  $\text{TIL}^{(\text{Basic})}$  (Fig. 2b) demonstrates that there was considerably more change in  $\text{TIL}^{(\text{Basic})}$  from  
400 day one to day two than there was in any other pair of consecutive days. On the rest of  
401 the days in the first week, 69–75% of the population did not experience a change in  
402  $\text{TIL}^{(\text{Basic})}$  from one day to the next (Fig. 2b). The distribution of next-day  $\text{TIL}^{(\text{Basic})}$  given the  
403 current day's  $\text{TIL}^{(\text{Basic})}$  (Supplementary Fig. S3) show that at least 79% of day-to-day  
404 therapeutic transitions happen within one  $\text{TIL}^{(\text{Basic})}$  category, except for escalations from  
405  $\text{TIL}^{(\text{Basic})}=0$  and de-escalations from  $\text{TIL}^{(\text{Basic})}=4$  from day one to two. When a change in  
406  $\text{TIL}^{(\text{Basic})}$  did occur, the distributions of  $\text{TIL}^{(\text{Basic})}$  before and after the change  
407 (Supplementary Fig. S4) reflect a gradual trend towards de-escalation at later days of ICU  
408 stay as expected.

409



411 **Fig. 2. Distributions of TIL<sup>(Basic)</sup> and its day-to-day changes in the study population.** (a) Alluvial  
 412 diagram of the evolution of the TIL<sup>(Basic)</sup> distribution in the study population over the assessed days of ICU  
 413 stay. Percentages which round to 2% or lower are not shown. (b) Distributions of day-to-day changes in  
 414 TIL<sup>(Basic)</sup>. The numbers above each bar represent the number of study patients remaining in the ICU after  
 415 the corresponding day-to-day step. Percentages which round to 2% or lower are not shown. Abbreviations:  
 416 ICU=intensive care unit, TIL=Therapy Intensity Level, TIL<sup>(Basic)</sup>=condensed, five-category TIL scale as  
 417 defined in Table 1, WLST=withdrawal of life-sustaining therapies.

418

## 419 **Reliability and performance of TILTomorrow**


420

421 With both calibration slopes (Fig. 1c) and smoothed calibration curves (Fig. 1d) across  
 422 the thresholds of next-day TIL<sup>(Basic)</sup>, we observed that the TILTomorrow modelling strategy  
 423 achieved sufficient testing set calibration for analysis from day two of ICU stay onwards.  
 424 The 95% CI of the calibration slope pertaining to prediction of next-day TIL<sup>(Basic)</sup> > 0 was  
 425 wider than that of other thresholds but still centred around a well-calibrated slope of one.  
 426

427

428 In the first week of ICU stay, TILTomorrow correctly discriminated patients at each  
 429 threshold of next-day TIL<sup>(Basic)</sup> between 79% (95% CI: 77–82%) and 95% (95% CI: 93–  
 430 96%) of the time (Fig. 3a). However, this apparently strong predictive power was in fact  
 431 largely because TIL<sup>(Basic)</sup> tended not to change greatly (i.e., the “inertia” of TIL) across  
 432 day-to-day steps (Fig. 2b), especially at higher thresholds of next-day TIL<sup>(Basic)</sup> (violet lines  
 433 in Fig. 3a). After removing all treatments and physician-based impressions from the model  
 434 variable set (including all variables related to TIL), the first-week AUCs dropped to  
 435 between 0.65 (95% CI: 0.62–0.68) and 0.86 (95% CI: 0.82–0.89) with significantly lower  
 436 performance at higher thresholds of next-day TIL<sup>(Basic)</sup> (Fig. 3a). Models trained with only  
 437 static variables achieved only marginally better discrimination than an uninformative  
 predictor (best AUC: 0.60 [95% CI: 0.56–0.63], Fig. 3a).

438



440 **Fig. 3. Differential performance in discriminating and explaining next-day TIL<sup>(Basic)</sup>.** All shaded regions  
 441 surrounding curves and error bars are 95% confidence intervals derived using bias-corrected bootstrapping  
 442 (1,000 resamples) to represent the variation across 20 repeated five-fold cross-validation partitions. (a)  
 443 Discrimination performance in prediction of next-day TIL<sup>(Basic)</sup> – measured by AUC at each threshold of  
 444 TIL<sup>(Basic)</sup> – by models trained on different variable sets. The violet line represents the performance achieved  
 445 by simply carrying the last available TIL<sup>(Basic)</sup> forward to account for the effect of day-to-day stasis in TIL<sup>(Basic)</sup>  
 446 on prediction. The horizontal dashed line (AUC=0.5) represents the performance of uninformative  
 447 prediction. (b) Discrimination performance in prediction of next-day de-escalation or escalation in TIL<sup>(Basic)</sup>  
 448 – measured by AUC – by models trained on different variable sets. The horizontal dashed line (AUC=0.5)  
 449 represents the performance of uninformative prediction. (c) Explanation of ordinal variation in next-day  
 450 changes in TIL<sup>(Basic)</sup> – measured by Somers'  $D_{xy}$  – by models trained on different variable sets.  
 451 Abbreviations: AUC=area under the receiver operating characteristic (ROC) curve, ICU=intensive care unit,  
 452 TIL=Therapy Intensity Level, TIL<sup>(Basic)</sup>=condensed, five-category TIL scale as defined in Table 1.

453  
 454 To completely account for the inertia of TIL<sup>(Basic)</sup> across day-to-day steps, we calculated  
 455 discrimination performance in the prediction of changes in next-day TIL<sup>(Basic)</sup> (Fig. 3b).  
 456 Prediction performance was highest on day one across all variable sets, with the full-  
 457 variable model correctly discriminating next-day de-escalations 90% (95% CI: 88–91%)  
 458 of the time and next-day escalations 85% (95% CI: 83–87%) of the time. Within each  
 459 variable set, change-in-TIL<sup>(Basic)</sup> prediction performance did not change significantly from  
 460 day two onwards, except for the prediction of next-day escalation from static variables.  
 461 Treatment and physician-based impression variables significantly improved performance  
 462 in prediction of next-day de-escalations in TIL<sup>(Basic)</sup> but not in prediction of next-day  
 463 escalations in TIL<sup>(Basic)</sup> (Fig. 3b). Moreover, static variables achieved greater

464 discrimination in the prediction of TIL<sup>(Basic)</sup> escalations than in the prediction of TIL<sup>(Basic)</sup>  
465 de-escalations from days two to four of ICU stay.  
466

### 467 ***Differential explanation of next-day changes in TIL***

468  
469 The full set of 2,008 variables explained 68% (95% CI: 65–72%) of the ordinal variation  
470 in next-day changes in TIL<sup>(Basic)</sup> on day one and up to 51% (95% CI: 45–56%) through the  
471 rest of the first week (Fig. 3c). For the same endpoint, the 1,803 variables which exclude  
472 treatments and physician-based impressions explained 60% (95% CI: 57–64%) of the  
473 ordinal variation on day one and up to 35% (95% CI: 30–41%) thereafter (Fig. 3c). From  
474 Fig. 3b, we found that the explanation added from the prior trajectory of ICU management  
475 related more to informative patterns of treatment de-escalation than to those of  
476 escalation. At the same time, most of the explanation achieved by the full variable model  
477 could also be achieved without explicit information about the patient's treatments. The  
478 1,029 static variables explained 54% (95% CI: 50–57%) of the ordinal variation in next-  
479 day changes in TIL<sup>(Basic)</sup> on day one and decreased in explanation significantly from days  
480 two (28% [95% CI: 23–33%]) to six (13% [95% CI: 7–19%]) (Fig. 3c). In other words, the  
481 explanatory impact of dynamic variables increased over time in the ICU. Most of the  
482 explanatory information in static variables contributed towards prediction of treatment  
483 escalations earlier in patients' ICU stays (Fig. 3b).  
484


### 485 ***Variables associated with next-day changes in TIL***

486  
487 During the days of consecutive TIL assessment that were eligible for  $\Delta$ TimeSHAP  
488 calculation (days 2–7), 575 patients (68% of population) experienced a total of 1,004 day-  
489 to-day changes in TIL<sup>(Basic)</sup>. The associative contributions of highest-impact variables  
490 towards prediction of these changes – both for models trained on all variables and for  
491 those trained without treatment variables – are visualised in Fig. 4. The number of points  
492 for each variable in Fig. 4 equals the number of times each variable was represented  
493 across the 1,004 changes in TIL<sup>(Basic)</sup>. Moreover, we annotated several specific values of  
494 categorical variables in Fig. 4 because of their visually consistent association with next-  
495 day TIL<sup>(Basic)</sup> de-escalation (i.e., negative  $\Delta$ TimeSHAP) or TIL<sup>(Basic)</sup> escalation (i.e.,  
496 positive  $\Delta$ TimeSHAP). Across the leading predictors of next-day changes in TIL<sup>(Basic)</sup> (Fig.  
497 4), we found the following categories of variables:

- 498 • the preceding trajectory of ICU management (e.g., extubation, prior trajectory of
- 499 TIL, ending nasogastric feeding),
- 500 • age at admission,
- 501 • bleeding risk factors (e.g., history of taking anticoagulants, baseline platelet count),
- 502 • brain imaging results (e.g., traumatic subarachnoid haemorrhage, subdural
- 503 haematoma, intraparenchymal haemorrhage),
- 504 • haemodynamics and intracranial hypertension (e.g., ICP, blood pressure,
- 505 respiratory efficiency),
- 506 • markers of systemic inflammation (e.g., ventilator-associated pneumonia [which
- 507 may also reflect long ventilation time], eosinophils),
- 508 • metabolic derangements (e.g., sodium, calcium, alanine aminotransferase),



- 509 • neurological function (e.g., Glasgow Coma Scale [GCS] eye and motor scores),
- 510 • protein biomarkers (e.g., neurofilament-light chain, total tau protein).
- 511



512 **Fig 4. Population-level variable contributions to prediction of changes in next-day TIL<sup>(Basic)</sup> at days**  
 513 **directly preceding a change in TIL<sup>(Basic)</sup>.** The ΔTimeSHAP values on the left panel are from the models  
 514 trained on the full variable set whilst the ΔTimeSHAP values on the right panel are from the models trained  
 515 without clinician impressions or treatments. ΔTimeSHAP values are interpreted as the relative contributions  
 516 of variables towards the difference in model prediction of next-day TIL<sup>(Basic)</sup> over the two days directly  
 517 preceding the change in TIL<sup>(Basic)</sup> (Supplementary Methods S5). Therefore, the study population  
 518 represented in this figure is limited to patients who experienced a change in TIL<sup>(Basic)</sup> after day two of ICU  
 519 stay ( $n = 575$ ). A positive ΔTimeSHAP value signifies association with an increased likelihood of escalation  
 520 in next-day TIL<sup>(Basic)</sup>, whereas a negative ΔTimeSHAP value signifies association with an increased  
 521 likelihood of de-escalation. The variables were selected by first identifying the ten variables with non-  
 522 missing value tokens with the most negative median ΔTimeSHAP values across the population (above the  
 523 ellipses) and then, amongst the remaining variables, selecting the ten with non-missing value tokens with  
 524 the most positive median ΔTimeSHAP values (below the ellipses). Each point represents the mean  
 525 ΔTimeSHAP value, taken across all 20 repeated cross-validation partitions, for a token preceding an  
 526 individual patient's change in TIL<sup>(Basic)</sup>. The number of points for each variable, therefore, indicates the  
 527 relative occurrence of that variable before changes in TIL<sup>(Basic)</sup> in the study population. The colour of the  
 528 point represents the relative ordered value of a token within a variable, and for unordered variables (e.g.,  
 529 patient status during GCS assessment), tokens were sorted alphanumerically (the sort index per possible  
 530 unordered variable token is provided in the CENTER-TBI data dictionary: [https://www.center-](https://www.center-tbi.eu/data/dictionary)  
 531 [tbi.eu/data/dictionary](https://www.center-tbi.eu/data/dictionary)). Abbreviations: CVDs=cardiovascular diseases, ER=emergency room, F<sub>I</sub>O<sub>2</sub>=fraction  
 532 of inspired oxygen, GCS=Glasgow Coma Scale, ICP=intracranial pressure, P<sub>a</sub>O<sub>2</sub>=partial pressure of  
 533

534 oxygen, TIL=Therapy Intensity Level, TIL<sup>(Basic)</sup>=condensed, five-category TIL scale as defined in Table 1,  
535 VAP=ventilator-associated pneumonia.

536  
537 The most robust predictors of next-day de-escalation in TIL<sup>(Basic)</sup> were other clinical  
538 indicators of treatment de-escalation (e.g., ending nasogastric feeding), improvement in  
539 patients' eye-opening responses, previous administration of barbiturates or propofol, and  
540 sufficient control of ICP. Overall, the effects of predictors for TIL<sup>(Basic)</sup> escalation were not  
541 as robust as those for de-escalation (Fig. 4); however, stratifying the  $\Delta$ TimeSHAP values  
542 by the pre-transition TIL<sup>(Basic)</sup> score revealed more consistent associations per level of  
543 treatment intensity (Supplementary Fig. S5). For example, high ICP values were robustly  
544 predictive of escalations from TIL<sup>(Basic)</sup>=2, and the prior administration of certain therapies  
545 could be predictive of a future escalation or de-escalation based on the current TIL<sup>(Basic)</sup>  
546 score (Supplementary Fig. S5). Apart from treatment variables, the factors that  
547 contributed the most towards prediction of de-escalation from extreme ICP management  
548 (i.e., TIL<sup>(Basic)</sup>=4) were neurological improvements in motor and eye response with  
549 sufficiently controlled ICP and high blood oxygen saturation (Supplementary Fig. S5). The  
550  $\Delta$ TimeSHAP values of missing variables (Supplementary Fig. S6) demonstrated that  
551 missingness of a variable (e.g., missing report of daily complications) could have a  
552 significant de-escalating associative effect on model output.


553

### 554 ***Conceptual model of changes in treatment intensity***

555

556 We combined the results from the differential explanation of next-day changes in TIL<sup>(Basic)</sup>  
557 (Fig. 3b–c) and the variable contributions towards prediction of these events (Fig. 4) to  
558 produce a conceptual model of day-to-day changes in treatment intensity (Fig. 5). Given  
559 the considerable difference in explanation performance between day one and subsequent  
560 days of ICU stay, we separated these explanation percentages in our model.

561



562  
 563 **Fig 5. Conceptual diagram of factors explaining day-to-day changes in therapeutic intensity.** The  
 564 percentage values represent the differential explanation of ordinal variation in next-day changes in TIL<sup>(Basic)</sup>  
 565 as measured by Somers'  $D_{xy}$ . The bolded percentage values represent the 95% confidence interval of  
 566 Somers'  $D_{xy}$  from days 2–6 of ICU stay, whilst the percentage values below them represent the 95%  
 567 confidence interval of Somers'  $D_{xy}$  from day 1 of ICU stay (Fig. 3c). The 95% confidence intervals were  
 568 derived using bias-corrected bootstrapping (1,000 resamples) to represent the variation across 20 repeated  
 569 five-fold cross-validation partitions. The leading static and dynamic pathophysiological factors were  
 570 determined by qualitative categorisation of the variables with the highest contribution to next-day changes  
 571 in TIL<sup>(Basic)</sup> based on  $\Delta$ TimeSHAP values (Fig. 4). Abbreviations: TIL=Therapy Intensity Level,  
 572 TIL<sup>(Basic)</sup>=condensed, five-category TIL scale as defined in Table 1.

573

## 574 Discussion

575

576 We present the first approach to dynamic prediction of future therapy intensity levels (TIL)  
 577 in ICP-monitored TBI patients. The TILTomorrow modelling strategy allowed us to exploit  
 578 the full clinical context (2,008 variables) captured in a large neurotrauma dataset over  
 579 time to uncover factors associated with next-day changes in TIL<sup>(Basic)</sup>.<sup>19</sup> By including  
 580 missing value tokens, models discovered meaningful patterns of missingness  
 581 (Supplementary Fig. S6).<sup>20</sup> Moreover, our approach mapped clinical events to evolving  
 582 predictions at each ordinal level of next-day TIL<sup>(Basic)</sup>, which is an improvement in  
 583 statistical power and clinical information over using a dichotomised measure of  
 584 therapeutic intensity (e.g., high-TIL therapies).<sup>15</sup>

585

586 The main results of this study are summarised in the conceptual diagram of changes in  
 587 TIL<sup>(Basic)</sup> (Fig. 5). Amongst all day-to-day steps, the transition from day one to day two had

588 the greatest number of changes in TIL<sup>(Basic)</sup> (Fig. 2b), which were also the most predictable  
589 (68% [95% CI: 65–72%] explanation, Fig. 3c). From day two onwards, the ordinal  
590 explanation of changes in next-day TIL<sup>(Basic)</sup> dropped to between 39% (95% CI: 32–47%)  
591 and 51% (95% CI: 45–56%). This difference suggests that first-to-second-day changes  
592 in treatment intensity might have been the most systematic, possibly associated with  
593 primary injury severity and initial patient responses to treatment (Fig. 3c). Later in ICU  
594 stay, the predictive influence of a patient's treatment trajectory increased (mostly through  
595 informative patterns of de-escalation, Fig. 3b), and that of static factors decreased (Fig.  
596 3c). Whilst static factors are poor predictors of TIL<sup>(Basic)</sup> on any given day (Fig. 3a and as  
597 shown previously<sup>12</sup>), they achieve considerable discrimination performance in prediction  
598 of escalations up to day four (AUC: 0.70 [95% CI: 0.65–0.74], Fig. 3b). This may indicate  
599 the potential of certain primary injury factors for justifying earlier intervention as to avoid  
600 tolerating suboptimal ICP management for a few days. Apart from age, the highest-  
601 contributing static factors were space-occupying lesions (also reflected in a recent  
602 study<sup>28</sup>) and bleeding risk factors (Fig. 4), both of which can complicate ICP control. As  
603 targets of TIL therapies, ICP and haemodynamic factors are expectedly high-contributing,  
604 with different effects based on the pre-transition TIL<sup>(Basic)</sup> score (Supplementary Fig. S5).  
605 Metabolic complications (i.e., abnormalities in renal or liver function and electrolytic  
606 imbalances) have previously been shown to be significantly more common in patients  
607 receiving high-TIL therapies<sup>12</sup> and an important marker for physiological endotyping.<sup>29</sup>  
608 Moreover, in a prior study, serial protein biomarkers (in addition to GCS) were key  
609 descriptors for clustering TBI patient trajectories in the ICU.<sup>30</sup> Therefore, the results from  
610 these dynamic variables support the links between TIL and pathophysiology – including  
611 systemic factors (e.g., metabolism and inflammation) – after TBI.<sup>7</sup> This is potentially of  
612 clinical importance since protein biomarkers are not measured serially as part of typical  
613 routine care outside of research studies (e.g., CENTER-TBI) and a few centres. It is still  
614 uncertain whether serial biomarker measurement would improve care outcomes.  
615 However, analysing the temporal dynamics of these biomarkers may not only enable a  
616 more precise characterisation of patients' treatment needs but also elucidate biological  
617 mechanisms underpinning variable treatment response. Finally, whilst we found no  
618 significant difference in full-model prediction performance between next-day escalations  
619 and de-escalations of TIL<sup>(Basic)</sup> (Fig. 3b), high-impact predictors had a more robust signal  
620 with de-escalations than they did with escalations (i.e., more consistently negative  
621  $\Delta$ TimeSHAP values in Fig. 4). This suggests that escalation prediction may be the effect  
622 of a complex interaction of factors which is difficult to perceive with  $\Delta$ TimeSHAP values.

623  
624 The underlying assumption of this work is that a more protocolised management of ICP  
625 would also be more predictable based on the dynamic condition of a TBI patient. Even  
626 with wide inter-centre variation in ICP-targeting treatment,<sup>14</sup> we would expect the  
627 measurable factors which rationally drive day-to-day changes in TIL to predict such  
628 changes on an individual level. After day two, approximately half of the ordinal variation  
629 in day-to-day changes in TIL<sup>(Basic)</sup> is unexplained by the full CENTER-TBI variable set,  
630 and we propose four reasons for this remaining uncertainty (Fig. 5). First, certain clinical  
631 events or complications that could suddenly trigger a (de-)escalation in TIL (e.g.,  
632 sustained rise in ICP) might not have been predictable from the day before. Second, there  
633 are probably important physiological factors, either unmeasured or not included in our

634 variable set, which would have improved TIL prediction. Most notably, high-resolution  
635 waveforms of ICP<sup>31</sup> and arterial blood pressure (ABP) and their derived metrics (e.g.,  
636 pressure-time dose<sup>32</sup> and vascular reactivity<sup>33</sup>) are more likely to elucidate ICP  
637 management decisions than the bihourly clinician-recorded ICP or CPP values available  
638 in our variable set.<sup>34</sup> Prior analyses of additional physiological modalities – e.g., cerebral  
639 microdialysis,<sup>35</sup> automated pupillometry,<sup>36,37</sup> and motion sensing<sup>38</sup> – have also  
640 demonstrated independent associations with TIL or other short-term endpoints after TBI.  
641 Third, assuming different centres have different protocols for ICP management, there may  
642 not have been enough patient representation across the spectrum of TBI severity from  
643 each centre for TILTomorrow to learn centre-specific guidelines. Fourth, a part of ICP  
644 management may be driven by the personal preferences of clinicians in deviation from  
645 general guidelines. At the same time, we recognise that predictability does not guarantee  
646 a systematised delivery of care. We therefore investigated differential explanation of (Fig.  
647 3b–c) and specific variable contributions towards (Fig. 4) changes in TIL to bridge  
648 prediction performance to a plausible concept of ICP management (Fig. 5).

649  
650 Our results support the use of TIL as an intermediate outcome after TBI.<sup>7</sup> Specific  
651 categories of pathophysiological variables – both static and dynamic – associate well with  
652 changes in TIL (Fig. 4 and 5). Since TIL rates the relative risk and complexity of  
653 administered treatments, it is logical to minimise TIL when all other factors are held equal.  
654 On the other hand, TIL is also a complicated marker of pathophysiology. Since around  
655 half of the ordinal variation in changes in TIL is not explained by measured variables (Fig.  
656 5), we hypothesise that TIL’s sensitivity to pathophysiology is partially confounded by the  
657 personal preferences of clinical teams. Nevertheless, TIL was previously shown to be a  
658 stronger indicator of refractory intracranial hypertension than ICP itself and, thus, a more  
659 suitable intermediate endpoint for TBI management.<sup>7</sup> Since the full information pertaining  
660 to TIL was only date-stamped in CENTER-TBI, the highest resolution at which we could  
661 assess TIL<sup>(Basic)</sup> was once per calendar day (Table 1). However, clinicians were also  
662 asked to record qualitatively whether treatment intensity was decreasing or increasing  
663 every four hours, and these indications (from the day before a change in TIL<sup>(Basic)</sup>) were  
664 amongst the strongest predictors of next-day changes in TIL<sup>(Basic)</sup> (Fig. 4). This result  
665 supports a higher resolution TIL for monitoring pathophysiological severity; however, daily  
666 TIL scores have been shown to be reliable estimates of hourly TIL scores,<sup>9</sup> and CENTER-  
667 TBI has demonstrated the practical feasibility of daily TIL assessment for a large-scale  
668 study ( $\leq 2.4\%$  missingness, Fig. 2a).

669  
670 TILTomorrow can potentially be useful in other heterogeneous-data-intensive clinical  
671 domains as a framework for decoding factors tied to treatment decision-making or other  
672 dynamic endpoints. This can inform the design of future causal inference models of  
673 individualised treatment effects from observational data.<sup>39</sup> TILTomorrow was not  
674 conceived for clinical deployment and should not be used for real-time decision support  
675 due to concerns of self-fulfilling prophecies, generalisability, and variable robustness.<sup>40</sup>  
676 Our focus was on explanatory modelling, to derive insightful patterns from the CENTER-  
677 TBI data and quantify the predictability of ICP management. Furthermore,  $\Delta$ TimeSHAP  
678 values on observational data are merely associative and cannot be interpreted for causal  
679 inference. We used TimeSHAP in this work to highlight potential areas of investigation

680 from a wider, data-driven approach. Pathophysiological predictors of the need for higher  
681 TIL (Fig. 4 and 5) could be useful for improving the timing and precision of future clinical  
682 decision-making (e.g., performing decompressive craniectomy in a timely but targeted  
683 way) but would require more evidence and feasibility studies than just their predictive  
684 power in our data.

685  
686 We recognise several additional limitations in this study. TILTomorrow discretised both  
687 numerical variables into binned tokens and time into daily windows, which caused some  
688 loss of information. Limited by the resolution of available TIL assessments, we chose a  
689 daily time window to avoid inconsistent lead times in our prediction task (Fig. 1a). The  
690 highest resolution of regularly recorded variables (e.g., ICP) in the CENTER-TBI core  
691 study is once every two hours,<sup>13</sup> and, since TILTomorrow takes the unique set of tokens  
692 per daily window prior to embedding, these numerical variables would be reduced to the  
693 unique set of quantiles represented in a day (Fig. 1b). An encoding strategy which can  
694 integrate high-resolution ICP, CPP, and other clinical information into broader time  
695 windows may improve prediction performance. Additionally, the daily TIL<sup>(Basic)</sup> score  
696 accounts for 33% of the information in the full, 38-point TIL score.<sup>7</sup> As explained in the  
697 Methods, we used TIL<sup>(Basic)</sup> as the model endpoint over the full TIL score since it would  
698 enable us to uncover factors associated with changes across specific, interpretable bands  
699 of treatment intensity (Table 1). Nevertheless, a regression-based prediction of next-day  
700 full TIL may capture more nuanced patterns of factors associated with changes in ICP  
701 management. Finally, our results may encode recruitment, collection, and clinical biases  
702 native to our European patient set. Selective recording of clinical data – with selective  
703 missingness – may have biased our analyses, and findings may not generalise to other  
704 populations.<sup>41</sup> Given the broad inter-centre variation in ICP-targeted care,<sup>14</sup> the results of  
705 TILTomorrow are likely to vary considerably depending on the protocols of specific  
706 centres. We encourage investigators to apply the TILTomorrow approach to other  
707 longitudinal, granular ICU datasets of TBI patients – particularly in low- and middle-  
708 income countries where the burden of TBI is disproportionately higher<sup>42</sup> – and compare  
709 their results.

710

## 711 **Data and code availability**

712

713 Individual participant data, including data dictionary, the study protocol, and analysis  
714 scripts are available online, conditional to approved study proposal, with no end date.  
715 Interested investigators must submit a study proposal to the management committee at  
716 <https://www.center-tbi.eu/data>. Signed confirmation of a data access agreement is  
717 required, and all access must comply with regulatory restrictions imposed on the original  
718 study.

719

720 All code used in this project can be found at the following online repository:  
721 <https://github.com/sbhattacharyay/TILTomorrow> (DOI: 10.5281/zenodo.11060742).

722

## 723 **Acknowledgments**

724

725 This research was supported by the National Institute for Health Research (NIHR) Brain  
726 Injury MedTech Co-operative. CENTER-TBI was supported by the European Union 7<sup>th</sup>  
727 Framework programme (EC grant 602150). Additional funding was obtained from the  
728 Hannelore Kohl Stiftung (Germany), from OneMind (USA), from Integra LifeSciences  
729 Corporation (USA), and from NeuroTrauma Sciences (USA). CENTER-TBI also  
730 acknowledges interactions and support from the International Initiative for TBI Research  
731 (InTBIR) investigators. S.B. is funded by a Gates Cambridge Scholarship. E.B. is funded  
732 by the Medical Research Council (MR N013433-1) and by a Gates Cambridge  
733 Scholarship. The funders had no role in study design, data collection and analysis,  
734 decision to publish, or preparation of the manuscript.

735  
736 We are grateful to the patients and families of our study for making our efforts to improve  
737 TBI care possible. S.B. would like to thank Kathleen Mitchell-Fox (Princeton University)  
738 for offering comments on the manuscript.

739

## 740 **The CENTER-TBI investigators and participants**

741  
742 The co-lead investigators of CENTER-TBI are designated with an asterisk (\*), and their  
743 contact email addresses are listed below.

744  
745 Cecilia Åkerlund<sup>1</sup>, Krisztina Amrein<sup>2</sup>, Nada Andelic<sup>3</sup>, Lasse Andreassen<sup>4</sup>, Audny Anke<sup>5</sup>,  
746 Anna Antoni<sup>6</sup>, Gérard Audibert<sup>7</sup>, Philippe Azouvi<sup>8</sup>, Maria Luisa Azzolini<sup>9</sup>, Ronald Bartels<sup>10</sup>,  
747 Pál Barzó<sup>11</sup>, Romuald Beauvais<sup>12</sup>, Ronny Beer<sup>13</sup>, Bo-Michael Bellander<sup>14</sup>, Antonio Belli<sup>15</sup>,  
748 Habib Benali<sup>16</sup>, Maurizio Berardino<sup>17</sup>, Luigi Beretta<sup>9</sup>, Morten Blaabjerg<sup>18</sup>, Peter Bragge<sup>19</sup>,  
749 Alexandra Brazinova<sup>20</sup>, Vibeke Brinck<sup>21</sup>, Joanne Brooker<sup>22</sup>, Camilla Brorsson<sup>23</sup>, Andras  
750 Buki<sup>24</sup>, Monika Bullinger<sup>25</sup>, Manuel Cabeleira<sup>26</sup>, Alessio Caccioppola<sup>27</sup>, Emiliana  
751 Calappi<sup>27</sup>, Maria Rosa Calvi<sup>9</sup>, Peter Cameron<sup>28</sup>, Guillermo Carbayo Lozano<sup>29</sup>, Marco  
752 Carbonara<sup>27</sup>, Simona Cavallo<sup>17</sup>, Giorgio Chevallard<sup>30</sup>, Arturo Chierogato<sup>30</sup>, Giuseppe  
753 Citerio<sup>31,32</sup>, Hans Clusmann<sup>33</sup>, Mark Coburn<sup>34</sup>, Jonathan Coles<sup>35</sup>, Jamie D. Cooper<sup>36</sup>,  
754 Marta Correia<sup>37</sup>, Amra Čović<sup>38</sup>, Nicola Curry<sup>39</sup>, Endre Czeiter<sup>24</sup>, Marek Czosnyka<sup>26</sup>, Claire  
755 Dahyot-Fizelier<sup>40</sup>, Paul Dark<sup>41</sup>, Helen Dawes<sup>42</sup>, Véronique De Keyser<sup>43</sup>, Vincent Degos<sup>16</sup>,  
756 Francesco Della Corte<sup>44</sup>, Hugo den Boogert<sup>10</sup>, Bart Depreitere<sup>45</sup>, Đula Đilvesi<sup>46</sup>, Abhishek  
757 Dixit<sup>47</sup>, Emma Donoghue<sup>22</sup>, Jens Dreier<sup>48</sup>, Guy-Loup Dulière<sup>49</sup>, Ari Ercole<sup>47</sup>, Patrick  
758 Esser<sup>42</sup>, Erzsébet Ezer<sup>50</sup>, Martin Fabricius<sup>51</sup>, Valery L. Feigin<sup>52</sup>, Kelly Foks<sup>53</sup>, Shirin  
759 Frisvold<sup>54</sup>, Alex Furmanov<sup>55</sup>, Pablo Gagliardo<sup>56</sup>, Damien Galanaud<sup>16</sup>, Dashiell Gantner<sup>28</sup>,  
760 Guoyi Gao<sup>57</sup>, Pradeep George<sup>58</sup>, Alexandre Ghuysen<sup>59</sup>, Lelde Giga<sup>60</sup>, Ben Glocker<sup>61</sup>,  
761 Jagoš Golubovic<sup>46</sup>, Pedro A. Gomez<sup>62</sup>, Johannes Gratz<sup>63</sup>, Benjamin Gravesteijn<sup>64</sup>,  
762 Francesca Grossi<sup>44</sup>, Russell L. Gruen<sup>65</sup>, Deepak Gupta<sup>66</sup>, Juanita A. Haagsma<sup>64</sup>, Iain  
763 Haitsma<sup>67</sup>, Raimund Helbok<sup>13</sup>, Eirik Helseth<sup>68</sup>, Lindsay Horton<sup>69</sup>, Jilske Huijben<sup>64</sup>, Peter  
764 J. Hutchinson<sup>70</sup>, Bram Jacobs<sup>71</sup>, Stefan Jankowski<sup>72</sup>, Mike Jarrett<sup>21</sup>, Ji-yao Jiang<sup>58</sup>, Faye  
765 Johnson<sup>73</sup>, Kelly Jones<sup>52</sup>, Mladen Karan<sup>46</sup>, Angelos G. Koliass<sup>70</sup>, Erwin Kompanje<sup>74</sup>, Daniel  
766 Kondziella<sup>51</sup>, Evgenios Kornaropoulos<sup>47</sup>, Lars-Owe Koskinen<sup>75</sup>, Noémi Kovács<sup>76</sup>, Ana  
767 Kowark<sup>77</sup>, Alfonso Lagares<sup>62</sup>, Linda Lanyon<sup>58</sup>, Steven Laureys<sup>78</sup>, Fiona Lecky<sup>79,80</sup>, Didier  
768 Ledoux<sup>78</sup>, Rolf Lefering<sup>81</sup>, Valerie Legrand<sup>82</sup>, Aurelie Lejeune<sup>83</sup>, Leon Levi<sup>84</sup>, Roger  
769 Lightfoot<sup>85</sup>, Hester Lingsma<sup>64</sup>, Andrew I.R. Maas<sup>43,86,\*</sup>, Ana M. Castaño-León<sup>62</sup>, Marc  
770 Maegele<sup>87</sup>, Marek Majdan<sup>20</sup>, Alex Manara<sup>88</sup>, Geoffrey Manley<sup>89</sup>, Costanza Martino<sup>90</sup>,

771 Hugues Maréchal<sup>49</sup>, Julia Mattern<sup>91</sup>, Catherine McMahon<sup>92</sup>, Béla Melegh<sup>93</sup>, David  
772 Menon<sup>47,\*</sup>, Tomas Menovsky<sup>43,86</sup>, Ana Mikolic<sup>64</sup>, Benoit Misset<sup>78</sup>, Visakh  
773 Muraleedharan<sup>58</sup>, Lynnette Murray<sup>28</sup>, Ancuta Negru<sup>94</sup>, David Nelson<sup>1</sup>, Virginia  
774 Newcombe<sup>47</sup>, Daan Nieboer<sup>64</sup>, József Nyirádi<sup>2</sup>, Otesile Olubukola<sup>79</sup>, Matej Oresic<sup>95</sup>,  
775 Fabrizio Ortolano<sup>27</sup>, Aarno Palotie<sup>96,97,98</sup>, Paul M. Parizel<sup>99</sup>, Jean-François Payen<sup>100</sup>,  
776 Natascha Perera<sup>12</sup>, Vincent Perlberg<sup>16</sup>, Paolo Persona<sup>101</sup>, Wilco Peul<sup>102</sup>, Anna Piippo-  
777 Karjalainen<sup>103</sup>, Matti Pirinen<sup>96</sup>, Dana Pisica<sup>64</sup>, Horia Ples<sup>94</sup>, Suzanne Polinder<sup>64</sup>, Inigo  
778 Pomposo<sup>29</sup>, Jussi P. Posti<sup>104</sup>, Louis Puybasset<sup>105</sup>, Andreea Radoi<sup>106</sup>, Arminas  
779 Ragauskas<sup>107</sup>, Rahul Raj<sup>103</sup>, Malinka Rambadagalla<sup>108</sup>, Isabel Retel Helmrich<sup>64</sup>, Jonathan  
780 Rhodes<sup>109</sup>, Sylvia Richardson<sup>110</sup>, Sophie Richter<sup>47</sup>, Samuli Ripatti<sup>96</sup>, Saulius Rocka<sup>107</sup>,  
781 Cecilie Roe<sup>111</sup>, Olav Roise<sup>112,113</sup>, Jonathan Rosand<sup>114</sup>, Jeffrey V. Rosenfeld<sup>115</sup>, Christina  
782 Rosenlund<sup>116</sup>, Guy Rosenthal<sup>55</sup>, Rolf Rossaint<sup>77</sup>, Sandra Rossi<sup>101</sup>, Daniel Rueckert<sup>61</sup>  
783 Martin Rusnák<sup>117</sup>, Juan Sahuquillo<sup>106</sup>, Oliver Sakowitz<sup>91,118</sup>, Renan Sanchez-Porras<sup>118</sup>,  
784 Janos Sandor<sup>119</sup>, Nadine Schäfer<sup>81</sup>, Silke Schmidt<sup>120</sup>, Herbert Schoechl<sup>121</sup>, Guus  
785 Schoonman<sup>122</sup>, Rico Frederik Schou<sup>123</sup>, Elisabeth Schwendenwein<sup>6</sup>, Charlie Sewalt<sup>64</sup>,  
786 Ranjit D. Singh<sup>102</sup>, Toril Skandsen<sup>124,125</sup>, Peter Smielewski<sup>26</sup>, Abayomi Sorinola<sup>126</sup>,  
787 Emmanuel Stamatakis<sup>47</sup>, Simon Stanworth<sup>39</sup>, Robert Stevens<sup>127</sup>, William Stewart<sup>128</sup>,  
788 Ewout W. Steyerberg<sup>64,129</sup>, Nino Stocchetti<sup>130</sup>, Nina Sundström<sup>131</sup>, Riikka Takala<sup>132</sup>,  
789 Viktória Tamás<sup>126</sup>, Tomas Tamosuitis<sup>133</sup>, Mark Steven Taylor<sup>20</sup>, Aurore Thibaut<sup>78</sup>, Braden  
790 Te Ao<sup>52</sup>, Olli Tenovuo<sup>104</sup>, Alice Theadom<sup>52</sup>, Matt Thomas<sup>88</sup>, Dick Tibboel<sup>134</sup>, Marjolein  
791 Timmers<sup>74</sup>, Christos Tolia<sup>135</sup>, Tony Trapani<sup>28</sup>, Cristina Maria Tudora<sup>94</sup>, Andreas  
792 Unterberg<sup>91</sup>, Peter Vajkoczy<sup>136</sup>, Shirley Vallance<sup>28</sup>, Egils Valeinis<sup>60</sup>, Zoltán Vámos<sup>50</sup>,  
793 Mathieu van der Jagt<sup>137</sup>, Gregory Van der Steen<sup>43</sup>, Joukje van der Naalt<sup>71</sup>, Jeroen T.J.M.  
794 van Dijck<sup>102</sup>, Inge A. M. van Erp<sup>102</sup>, Thomas A. van Essen<sup>102</sup>, Wim Van Hecke<sup>138</sup>, Caroline  
795 van Heugten<sup>139</sup>, Ernest van Veen<sup>64</sup>, Thijs Vande Vyvere<sup>140</sup>, Roel P. J. van Wijk<sup>102</sup>, Alessia  
796 Vargiolu<sup>32</sup>, Emmanuel Vega<sup>83</sup>, Kimberley Velt<sup>64</sup>, Jan Verheyden<sup>138</sup>, Paul M. Vespa<sup>141</sup>,  
797 Anne Vik<sup>124,142</sup>, Rimantas Vilcinis<sup>133</sup>, Victor Volovici<sup>67</sup>, Nicole von Steinbüchel<sup>38</sup>, Daphne  
798 Voormolen<sup>64</sup>, Petar Vulekovic<sup>46</sup>, Kevin K.W. Wang<sup>143</sup>, Daniel Whitehouse<sup>47</sup>, Eveline  
799 Wieggers<sup>64</sup>, Guy Williams<sup>47</sup>, Lindsay Wilson<sup>69</sup>, Stefan Winzeck<sup>47</sup>, Stefan Wolf<sup>144</sup>, Zhihui  
800 Yang<sup>114</sup>, Peter Ylén<sup>145</sup>, Alexander Younsi<sup>91</sup>, Frederick A. Zeiler<sup>47,146</sup>, Veronika  
801 Zelinkova<sup>20</sup>, Agate Ziverte<sup>60</sup>, Tommaso Zoerle<sup>27</sup>

802  
803 <sup>1</sup>Department of Physiology and Pharmacology, Section of Perioperative Medicine and  
804 Intensive Care, Karolinska Institutet, Stockholm, Sweden

805 <sup>2</sup>János Szentágothai Research Centre, University of Pécs, Pécs, Hungary

806 <sup>3</sup>Division of Clinical Neuroscience, Department of Physical Medicine and Rehabilitation,  
807 Oslo University Hospital and University of Oslo, Oslo, Norway

808 <sup>4</sup>Department of Neurosurgery, University Hospital Northern Norway, Tromsø, Norway

809 <sup>5</sup>Department of Physical Medicine and Rehabilitation, University Hospital Northern  
810 Norway, Tromsø, Norway

811 <sup>6</sup>Trauma Surgery, Medical University Vienna, Vienna, Austria

812 <sup>7</sup>Department of Anesthesiology & Intensive Care, University Hospital Nancy, Nancy,  
813 France

814 <sup>8</sup>Raymond Poincaré hospital, Assistance Publique – Hôpitaux de Paris, Paris, France

815 <sup>9</sup>Department of Anesthesiology & Intensive Care, S Raffaele University Hospital, Milan,  
816 Italy



- 817 <sup>10</sup>Department of Neurosurgery, Radboud University Medical Center, Nijmegen, The  
818 Netherlands
- 819 <sup>11</sup>Department of Neurosurgery, University of Szeged, Szeged, Hungary
- 820 <sup>12</sup>International Projects Management, ARTTIC, Munchen, Germany
- 821 <sup>13</sup>Department of Neurology, Neurological Intensive Care Unit, Medical University of  
822 Innsbruck, Innsbruck, Austria
- 823 <sup>14</sup>Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska  
824 University Hospital, Stockholm, Sweden
- 825 <sup>15</sup>NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK
- 826 <sup>16</sup>Anesthésie-Réanimation, Assistance Publique – Hôpitaux de Paris, Paris, France
- 827 <sup>17</sup>Department of Anesthesia & ICU, AOU Città della Salute e della Scienza di Torino -  
828 Orthopedic and Trauma Center, Torino, Italy
- 829 <sup>18</sup>Department of Neurology, Odense University Hospital, Odense, Denmark
- 830 <sup>19</sup>BehaviourWorks Australia, Monash Sustainability Institute, Monash University, Victoria,  
831 Australia
- 832 <sup>20</sup>Department of Public Health, Faculty of Health Sciences and Social Work, Trnava  
833 University, Trnava, Slovakia
- 834 <sup>21</sup>Quesgen Systems Inc., Burlingame, California, USA
- 835 <sup>22</sup>Australian & New Zealand Intensive Care Research Centre, Department of  
836 Epidemiology and Preventive Medicine, School of Public Health and Preventive  
837 Medicine, Monash University, Melbourne, Australia
- 838 <sup>23</sup>Department of Surgery and Perioperative Science, Umeå University, Umeå, Sweden
- 839 <sup>24</sup>Department of Neurosurgery, Medical School, University of Pécs, Hungary and  
840 Neurotrauma Research Group, János Szentágothai Research Centre, University of  
841 Pécs, Hungary
- 842 <sup>25</sup>Department of Medical Psychology, Universitätsklinikum Hamburg-Eppendorf,  
843 Hamburg, Germany
- 844 <sup>26</sup>Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences, University  
845 of Cambridge, Addenbrooke's Hospital, Cambridge, UK
- 846 <sup>27</sup>Neuro ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
- 847 <sup>28</sup>ANZIC Research Centre, Monash University, Department of Epidemiology and  
848 Preventive Medicine, Melbourne, Victoria, Australia
- 849 <sup>29</sup>Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain
- 850 <sup>30</sup>NeuroIntensive Care, Niguarda Hospital, Milan, Italy
- 851 <sup>31</sup>School of Medicine and Surgery, Università Milano Bicocca, Milano, Italy
- 852 <sup>32</sup>NeuroIntensive Care Unit, Department Neuroscience, IRCCS Fondazione San Gerardo  
853 dei Tintori, Monza, Italy
- 854 <sup>33</sup>Department of Neurosurgery, Medical Faculty RWTH Aachen University, Aachen,  
855 Germany
- 856 <sup>34</sup>Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn,  
857 Bonn, Germany
- 858 <sup>35</sup>Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS  
859 Foundation Trust, Cambridge, UK
- 860 <sup>36</sup>School of Public Health & PM, Monash University and The Alfred Hospital, Melbourne,  
861 Victoria, Australia
- 862 <sup>37</sup>Radiology/MRI department, MRC Cognition and Brain Sciences Unit, Cambridge, UK

- 863 <sup>38</sup>Institute of Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen,  
864 Göttingen, Germany
- 865 <sup>39</sup>Oxford University Hospitals NHS Trust, Oxford, UK
- 866 <sup>40</sup>Intensive Care Unit, CHU Poitiers, Poitiers, France
- 867 <sup>41</sup>University of Manchester NIHR Biomedical Research Centre, Critical Care Directorate,  
868 Salford Royal Hospital NHS Foundation Trust, Salford, UK
- 869 <sup>42</sup>Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes  
870 University, Oxford, UK
- 871 <sup>43</sup>Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium
- 872 <sup>44</sup>Department of Anesthesia & Intensive Care, Maggiore Della Carità Hospital, Novara,  
873 Italy
- 874 <sup>45</sup>Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium
- 875 <sup>46</sup>Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine,  
876 University of Novi Sad, Novi Sad, Serbia
- 877 <sup>47</sup>Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge,  
878 UK
- 879 <sup>48</sup>Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin, corporate  
880 member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute  
881 of Health, Berlin, Germany
- 882 <sup>49</sup>Intensive Care Unit, CHR Citadelle, Liège, Belgium
- 883 <sup>50</sup>Department of Anaesthesiology and Intensive Therapy, University of Pécs, Pécs,  
884 Hungary
- 885 <sup>51</sup>Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region  
886 Hovedstaden Rigshospitalet, Copenhagen, Denmark
- 887 <sup>52</sup>National Institute for Stroke and Applied Neurosciences, Faculty of Health and  
888 Environmental Studies, Auckland University of Technology, Auckland, New Zealand
- 889 <sup>53</sup>Department of Neurology, Erasmus MC, Rotterdam, the Netherlands
- 890 <sup>54</sup>Department of Anesthesiology and Intensive care, University Hospital Northern Norway,  
891 Tromsø, Norway
- 892 <sup>55</sup>Department of Neurosurgery, Hadassah-hebrew University Medical center, Jerusalem,  
893 Israel
- 894 <sup>56</sup>Fundación Instituto Valenciano de Neurorehabilitación (FIVAN), Valencia, Spain
- 895 <sup>57</sup>Department of Neurosurgery, Shanghai Renji hospital, Shanghai Jiaotong  
896 University/school of medicine, Shanghai, China
- 897 <sup>58</sup>Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility,  
898 Stockholm, Sweden
- 899 <sup>59</sup>Emergency Department, CHU, Liège, Belgium
- 900 <sup>60</sup>Neurosurgery clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia
- 901 <sup>61</sup>Department of Computing, Imperial College London, London, UK
- 902 <sup>62</sup>Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain
- 903 <sup>63</sup>Department of Anesthesia, Critical Care and Pain Medicine, Medical University of  
904 Vienna, Austria
- 905 <sup>64</sup>Department of Public Health, Erasmus Medical Center-University Medical Center,  
906 Rotterdam, The Netherlands
- 907 <sup>65</sup>College of Health and Medicine, Australian National University, Canberra, Australia

- 908 <sup>66</sup>Department of Neurosurgery, Neurosciences Centre & JPN Apex trauma centre, All  
909 India Institute of Medical Sciences, New Delhi-110029, India
- 910 <sup>67</sup>Department of Neurosurgery, Erasmus MC, Rotterdam, the Netherlands
- 911 <sup>68</sup>Department of Neurosurgery, Oslo University Hospital, Oslo, Norway
- 912 <sup>69</sup>Division of Psychology, University of Stirling, Stirling, UK
- 913 <sup>70</sup>Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's  
914 Hospital & University of Cambridge, Cambridge, UK
- 915 <sup>71</sup>Department of Neurology, University of Groningen, University Medical Center  
916 Groningen, Groningen, Netherlands
- 917 <sup>72</sup>Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield,  
918 UK
- 919 <sup>73</sup>Salford Royal Hospital NHS Foundation Trust Acute Research Delivery Team, Salford,  
920 UK
- 921 <sup>74</sup>Department of Intensive Care and Department of Ethics and Philosophy of Medicine,  
922 Erasmus Medical Center, Rotterdam, The Netherlands
- 923 <sup>75</sup>Department of Clinical Neuroscience, Neurosurgery, Umeå University, Umeå, Sweden
- 924 <sup>76</sup>Hungarian Brain Research Program - Grant No. KTIA\_13\_NAP-A-II/8, University of  
925 Pécs, Pécs, Hungary
- 926 <sup>77</sup>Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany
- 927 <sup>78</sup>Cyclotron Research Center, University of Liège, Liège, Belgium
- 928 <sup>79</sup>Centre for Urgent and Emergency Care Research (CURE), Health Services Research  
929 Section, School of Health and Related Research (SchARR), University of Sheffield,  
930 Sheffield, UK
- 931 <sup>80</sup>Emergency Department, Salford Royal Hospital, Salford UK
- 932 <sup>81</sup>Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University,  
933 Cologne, Germany
- 934 <sup>82</sup>VP Global Project Management CNS, ICON, Paris, France
- 935 <sup>83</sup>Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France
- 936 <sup>84</sup>Department of Neurosurgery, Rambam Medical Center, Haifa, Israel
- 937 <sup>85</sup>Department of Anesthesiology & Intensive Care, University Hospitals Southampton  
938 NHS Trust, Southampton, UK
- 939 <sup>86</sup>Department of Translational Neuroscience, Faculty of Medicine and Health Science,  
940 University of Antwerp, Antwerp, Belgium
- 941 <sup>87</sup>Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic  
942 Surgery and Sportmedicine, Witten/Herdecke University, Cologne, Germany
- 943 <sup>88</sup>Intensive Care Unit, Southmead Hospital, Bristol, Bristol, UK
- 944 <sup>89</sup>Department of Neurological Surgery, University of California, San Francisco, California,  
945 USA
- 946 <sup>90</sup>Department of Anesthesia & Intensive Care, M. Bufalini Hospital, Cesena, Italy
- 947 <sup>91</sup>Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
- 948 <sup>92</sup>Department of Neurosurgery, The Walton centre NHS Foundation Trust, Liverpool, UK
- 949 <sup>93</sup>Department of Medical Genetics, University of Pécs, Pécs, Hungary
- 950 <sup>94</sup>Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara,  
951 Romania
- 952 <sup>95</sup>School of Medical Sciences, Örebro University, Örebro, Sweden
- 953 <sup>96</sup>Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

- 954 <sup>97</sup>Analytic and Translational Genetics Unit, Department of Medicine; Psychiatric &  
955 Neurodevelopmental Genetics Unit, Department of Psychiatry; Department of  
956 Neurology, Massachusetts General Hospital, Boston, MA, USA
- 957 <sup>98</sup>Program in Medical and Population Genetics; The Stanley Center for Psychiatric  
958 Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 959 <sup>99</sup>Department of Radiology, University of Antwerp, Edegem, Belgium
- 960 <sup>100</sup>Department of Anesthesiology & Intensive Care, University Hospital of Grenoble,  
961 Grenoble, France
- 962 <sup>101</sup>Department of Anesthesia & Intensive Care, Azienda Ospedaliera Università di  
963 Padova, Padova, Italy
- 964 <sup>102</sup>Dept. of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands and  
965 Dept. of Neurosurgery, Medical Center Haaglanden, The Hague, The Netherlands
- 966 <sup>103</sup>Department of Neurosurgery, Helsinki University Central Hospital
- 967 <sup>104</sup>Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain Injury  
968 Centre, Turku University Hospital and University of Turku, Turku, Finland
- 969 <sup>105</sup>Department of Anesthesiology and Critical Care, Pitié -Salpêtrière Teaching Hospital,  
970 Assistance Publique, Hôpitaux de Paris and University Pierre et Marie Curie, Paris,  
971 France
- 972 <sup>106</sup>Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron  
973 Research Institute, Barcelona, Spain
- 974 <sup>107</sup>Department of Neurosurgery, Kaunas University of technology and Vilnius University,  
975 Vilnius, Lithuania
- 976 <sup>108</sup>Department of Neurosurgery, Rezekne Hospital, Latvia
- 977 <sup>109</sup>Department of Anaesthesia, Critical Care & Pain Medicine NHS Lothian & University  
978 of Edinburgh, Edinburgh, UK
- 979 <sup>110</sup>Director, MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK
- 980 <sup>111</sup>Department of Physical Medicine and Rehabilitation, Oslo University  
981 Hospital/University of Oslo, Oslo, Norway
- 982 <sup>112</sup>Division of Orthopedics, Oslo University Hospital, Oslo, Norway
- 983 <sup>113</sup>Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
- 984 <sup>114</sup>Broad Institute, Cambridge MA Harvard Medical School, Boston MA, Massachusetts  
985 General Hospital, Boston MA, USA
- 986 <sup>115</sup>National Trauma Research Institute, The Alfred Hospital, Monash University,  
987 Melbourne, Victoria, Australia
- 988 <sup>116</sup>Department of Neurosurgery, Odense University Hospital, Odense, Denmark
- 989 <sup>117</sup>International Neurotrauma Research Organisation, Vienna, Austria
- 990 <sup>118</sup>Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany
- 991 <sup>119</sup>Division of Biostatistics and Epidemiology, Department of Preventive Medicine,  
992 University of Debrecen, Debrecen, Hungary
- 993 <sup>120</sup>Department Health and Prevention, University Greifswald, Greifswald, Germany
- 994 <sup>121</sup>Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg,  
995 Austria
- 996 <sup>122</sup>Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands
- 997 <sup>123</sup>Department of Neuroanesthesia and Neurointensive Care, Odense University Hospital,  
998 Odense, Denmark

- 999 <sup>124</sup>Department of Neuromedicine and Movement Science, Norwegian University of  
1000 Science and Technology, NTNU, Trondheim, Norway
- 1001 <sup>125</sup>Department of Physical Medicine and Rehabilitation, St.Olavs Hospital, Trondheim  
1002 University Hospital, Trondheim, Norway
- 1003 <sup>126</sup>Department of Neurosurgery, University of Pécs, Pécs, Hungary
- 1004 <sup>127</sup>Division of Neuroscience Critical Care, John Hopkins University School of Medicine,  
1005 Baltimore, USA
- 1006 <sup>128</sup>Department of Neuropathology, Queen Elizabeth University Hospital and University of  
1007 Glasgow, Glasgow, UK
- 1008 <sup>129</sup>Dept. of Department of Biomedical Data Sciences, Leiden University Medical Center,  
1009 Leiden, The Netherlands
- 1010 <sup>130</sup>Department of Pathophysiology and Transplantation, Milan University, and  
1011 Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico,  
1012 Milano, Italy
- 1013 <sup>131</sup>Department of Radiation Sciences, Biomedical Engineering, Umeå University, Umeå,  
1014 Sweden
- 1015 <sup>132</sup>Perioperative Services, Intensive Care Medicine and Pain Management, Turku  
1016 University Hospital and University of Turku, Turku, Finland
- 1017 <sup>133</sup>Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania
- 1018 <sup>134</sup>Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia  
1019 Children's Hospital, Rotterdam, The Netherlands
- 1020 <sup>135</sup>Department of Neurosurgery, Kings college London, London, UK
- 1021 <sup>136</sup>Neurologie, Neurochirurgie und Psychiatrie, Charité – Universitätsmedizin Berlin,  
1022 Berlin, Germany
- 1023 <sup>137</sup>Department of Intensive Care Adults, Erasmus MC– University Medical Center  
1024 Rotterdam, Rotterdam, the Netherlands
- 1025 <sup>138</sup>icoMetrix NV, Leuven, Belgium
- 1026 <sup>139</sup>Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes  
1027 University, Oxford, UK
- 1028 <sup>140</sup>Radiology Department, Antwerp University Hospital, Edegem, Belgium
- 1029 <sup>141</sup>Director of Neurocritical Care, University of California, Los Angeles, USA
- 1030 <sup>142</sup>Department of Neurosurgery, St.Olavs Hospital, Trondheim University Hospital,  
1031 Trondheim, Norway
- 1032 <sup>143</sup>Department of Emergency Medicine, University of Florida, Gainesville, Florida, USA
- 1033 <sup>144</sup>Department of Neurosurgery, Charité – Universitätsmedizin Berlin, corporate member  
1034 of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of  
1035 Health, Berlin, Germany
- 1036 <sup>145</sup>VTT Technical Research Centre, Tampere, Finland
- 1037 <sup>146</sup>Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences,  
1038 University of Manitoba, Winnipeg, MB, Canada
- 1039
- 1040 \*Co-lead investigators: [andrew.maas@uza.be](mailto:andrew.maas@uza.be) (AIRM) and [dkm13@cam.ac.uk](mailto:dkm13@cam.ac.uk) (DM)
- 1041

## 1042 References

1043

- 1044 1 Meyfroidt G, Bouzat P, Casaer MP, *et al.* Management of moderate to severe  
1045 traumatic brain injury: an update for the intensivist. *Intensive Care Med* 2022; **48**:  
1046 649–66.
- 1047 2 Maas AIR, Menon DK, Adelson PD, *et al.* Traumatic brain injury: integrated  
1048 approaches to improve prevention, clinical care, and research. *Lancet Neurol* 2017;  
1049 **16**: 987–1048.
- 1050 3 Maas AIR, Menon DK, Manley GT, *et al.* Traumatic brain injury: progress and  
1051 challenges in prevention, clinical care, and research. *Lancet Neurol* 2022; **21**: 1004–  
1052 60.
- 1053 4 Hawryluk GWJ, Aguilera S, Buki A, *et al.* A management algorithm for patients with  
1054 intracranial pressure monitoring: the Seattle International Severe Traumatic Brain  
1055 Injury Consensus Conference (SIBICC). *Intensive Care Med* 2019; **45**: 1783–94.
- 1056 5 Carney N, Totten AM, O’Reilly C, *et al.* Guidelines for the Management of Severe  
1057 Traumatic Brain Injury, Fourth Edition. *Neurosurgery* 2017; **80**: 6.
- 1058 6 Stocchetti N, Maas AIR. Traumatic Intracranial Hypertension. *N Engl J Med* 2014;  
1059 **370**: 2121–30.
- 1060 7 Bhattacharyay S, Beqiri E, Zuercher P, *et al.* Therapy Intensity Level Scale for  
1061 Traumatic Brain Injury: Clinimetric Assessment on Neuro-Monitored Patients Across  
1062 52 European Intensive Care Units. *J Neurotrauma* 2024; **41**: 887–909.
- 1063 8 Maas AIR, Harrison-Felix CL, Menon D, *et al.* Standardizing Data Collection in  
1064 Traumatic Brain Injury. *J Neurotrauma* 2011; **28**: 177–87.
- 1065 9 Zuercher P, Groen JL, Aries MJH, *et al.* Reliability and Validity of the Therapy  
1066 Intensity Level Scale: Analysis of Clinimetric Properties of a Novel Approach to  
1067 Assess Management of Intracranial Pressure in Traumatic Brain Injury. *J*  
1068 *Neurotrauma* 2016; **33**: 1768–74.
- 1069 10 Maas AIR, Menon DK, Steyerberg EW, *et al.* Collaborative European NeuroTrauma  
1070 Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): A Prospective  
1071 Longitudinal Observational Study. *Neurosurgery* 2015; **76**: 67–80.
- 1072 11 Steyerberg EW, Wiegers E, Sewalt C, *et al.* Case-mix, care pathways, and  
1073 outcomes in patients with traumatic brain injury in CENTER-TBI: a European  
1074 prospective, multicentre, longitudinal, cohort study. *Lancet Neurol* 2019; **18**: 923–34.
- 1075 12 Huijben JA, Dixit A, Stocchetti N, *et al.* Use and impact of high intensity treatments  
1076 in patients with traumatic brain injury across Europe: a CENTER-TBI analysis. *Crit*  
1077 *Care* 2021; **25**: 78.

- 1078 13 Bhattacharyay S, Caruso PF, Åkerlund C, *et al.* Mining the contribution of intensive  
1079 care clinical course to outcome after traumatic brain injury. *Npj Digit Med* 2023; **6**: 1–  
1080 11.
- 1081 14 Huijben JA, Wiegers EJA, Lingsma HF, *et al.* Changing care pathways and  
1082 between-center practice variations in intensive care for traumatic brain injury across  
1083 Europe: a CENTER-TBI analysis. *Intensive Care Med* 2020; **46**: 995–1004.
- 1084 15 Bhattacharyay S, Milosevic I, Wilson L, *et al.* The leap to ordinal: Detailed functional  
1085 prognosis after traumatic brain injury with a flexible modelling approach. *PLOS ONE*  
1086 2022; **17**: e0270973.
- 1087 16 Doiron D, Marcon Y, Fortier I, Burton P, Ferretti V. Software Application Profile: Opal  
1088 and Mica: open-source software solutions for epidemiological data management,  
1089 harmonization and dissemination. *Int J Epidemiol* 2017; **46**: 1372–8.
- 1090 17 Monteiro M, Newcombe VFJ, Mathieu F, *et al.* Multiclass semantic segmentation  
1091 and quantification of traumatic brain injury lesions on head CT using deep learning:  
1092 an algorithm development and multicentre validation study. *Lancet Digit Health* 2020;  
1093 **2**: e314–22.
- 1094 18 Jain S, Vyvere TV, Terzopoulos V, *et al.* Automatic Quantification of Computed  
1095 Tomography Features in Acute Traumatic Brain Injury. *J Neurotrauma* 2019; **36**:  
1096 1794–803.
- 1097 19 Deasy J, Liò P, Ercole A. Dynamic survival prediction in intensive care units from  
1098 heterogeneous time series without the need for variable selection or curation. *Sci*  
1099 *Rep* 2020; **10**: 22129.
- 1100 20 Ercole A, Dixit A, Nelson DW, *et al.* Imputation strategies for missing baseline  
1101 neurological assessment covariates after traumatic brain injury: A CENTER-TBI  
1102 study. *PLOS ONE* 2021; **16**: e0253425.
- 1103 21 Tsamardinos I, Greasidou E, Borboudakis G. Bootstrapping the out-of-sample  
1104 predictions for efficient and accurate cross-validation. *Mach Learn* 2018; **107**: 1895–  
1105 922.
- 1106 22 Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A  
1107 calibration hierarchy for risk models was defined: from utopia to empirical data. *J Clin*  
1108 *Epidemiol* 2016; **74**: 167–76.
- 1109 23 Somers RH. A New Asymmetric Measure of Association for Ordinal Variables. *Am*  
1110 *Sociol Rev* 1962; **27**: 799–811.
- 1111 24 Van Calster B, Van Belle V, Vergouwe Y, Steyerberg EW. Discrimination ability of  
1112 prediction models for ordinal outcomes: Relationships between existing measures  
1113 and a new measure. *Biom J* 2012; **54**: 674–85.

- 1114 25 Bento J, Saleiro P, Cruz AF, Figueiredo MAT, Bizarro P. TimeSHAP: Explaining  
1115 Recurrent Models through Sequence Perturbations. In: Proceedings of the 27th ACM  
1116 SIGKDD Conference on Knowledge Discovery & Data Mining. New York, NY, USA:  
1117 Association for Computing Machinery, 2021: 2565–73.
- 1118 26 Lundberg SM, Lee S-I. A Unified Approach to Interpreting Model Predictions. In:  
1119 Guyon I, Luxburg UV, Bengio S, *et al.*, eds. Advances in Neural Information  
1120 Processing Systems 30. NIPS, 2017: 4765–74.
- 1121 27 Shapley LS. A Value for n-Person Games. In: Contributions to the Theory of Games  
1122 II. Princeton University Press, 1953: 307–18.
- 1123 28 Brossard C, Grèze J, de Busschère J-A, *et al.* Prediction of therapeutic intensity  
1124 level from automatic multiclass segmentation of traumatic brain injury lesions on CT-  
1125 scans. *Sci Rep* 2023; **13**: 20155.
- 1126 29 Åkerlund CAI, Holst A, Stocchetti N, *et al.* Clustering identifies endotypes of  
1127 traumatic brain injury in an intensive care cohort: a CENTER-TBI study. *Crit Care*  
1128 2022; **26**: 228.
- 1129 30 Åkerlund CAI, Holst A, Bhattacharyay S, *et al.* Clinical descriptors of disease  
1130 trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-  
1131 TBI): a multicentre observational cohort study. *Lancet Neurol* 2024; **23**: 71–80.
- 1132 31 Czosnyka M, Pickard JD. Monitoring and interpretation of intracranial pressure. *J*  
1133 *Neurol Neurosurg Psychiatry* 2004; **75**: 813–21.
- 1134 32 Åkerlund CAI, Donnelly J, Zeiler FA, *et al.* Impact of duration and magnitude of  
1135 raised intracranial pressure on outcome after severe traumatic brain injury: A  
1136 CENTER-TBI high-resolution group study. *PLOS ONE* 2020; **15**: e0243427.
- 1137 33 Beqiri E, Ercole A, Aries MJH, *et al.* Towards autoregulation-oriented management  
1138 after traumatic brain injury: increasing the reliability and stability of the CPPopt  
1139 algorithm. *J Clin Monit Comput* 2023; **37**: 963–76.
- 1140 34 Zoerle T, Birg T, Carbonara M, *et al.* Accuracy of Manual Intracranial Pressure  
1141 Recording Compared to a Computerized High-Resolution System: A CENTER-TBI  
1142 Analysis. *Neurocrit Care* 2023; **38**: 781–90.
- 1143 35 Eiden M, Christinat N, Chakrabarti A, *et al.* Discovery and validation of temporal  
1144 patterns involved in human brain ketometabolism in cerebral microdialysis fluids of  
1145 traumatic brain injury patients. *eBioMedicine* 2019; **44**: 607–17.
- 1146 36 Banco P, Taccone FS, Sourd D, *et al.* Prediction of neurocritical care intensity  
1147 through automated infrared pupillometry and transcranial doppler in blunt traumatic  
1148 brain injury: the NOPE study. *Eur J Trauma Emerg Surg* 2024; published online Jan  
1149 16. DOI:10.1007/s00068-023-02435-1.



- 1150 37 Luz Teixeira T, Peluso L, Banco P, *et al.* Early Pupillometry Assessment in  
1151 Traumatic Brain Injury Patients: A Retrospective Study. *Brain Sci* 2021; **11**: 1657.
- 1152 38 Bhattacharyay S, Rattray J, Wang M, *et al.* Decoding accelerometry for classification  
1153 and prediction of critically ill patients with severe brain injury. *Sci Rep* 2021; **11**:  
1154 23654.
- 1155 39 Bica I, Alaa AM, Lambert C, van der Schaar M. From Real-World Patient Data to  
1156 Individualized Treatment Effects Using Machine Learning: Current and Future  
1157 Methods to Address Underlying Challenges. *Clin Pharmacol Ther* 2020; **109**: 87–100.
- 1158 40 Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An  
1159 overview of clinical decision support systems: benefits, risks, and strategies for  
1160 success. *Npj Digit Med* 2020; **3**: 1–10.
- 1161 41 Futoma J, Simons M, Panch T, Doshi-Velez F, Celi LA. The myth of generalisability  
1162 in clinical research and machine learning in health care. *Lancet Digit Health* 2020; **2**:  
1163 e489–92.
- 1164 42 Clark D, Joannides A, Adeleye AO, *et al.* Casemix, management, and mortality of  
1165 patients receiving emergency neurosurgery for traumatic brain injury in the Global  
1166 Neurotrauma Outcomes Study: a prospective observational cohort study. *Lancet*  
1167 *Neurol* 2022; **21**: 438–49.
- 1168